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 This dissertation sheds light on several novel mechanistic findings in astrocyte 
specific gene regulation and function by the NFI-X transcription factor which can be 
further extrapolated to astrocyte differentiation and glial tumor invasion. First, we cloned 
and analyzed human NFI-X3, a novel splice variant of the nfix gene, which contains a 
unique transcriptional activation (TA) domain completely conserved in primates. In 
  
xvii 
xvii 
contrast to previously cloned NFI-X1, overexpression of NFI-X3 potently activates NFI 
reporters, including GFAP reporter, in astrocytes and glioma cells. The expression of 
NFI-X3 is dramatically upregulated during the differentiation of neural progenitors to 
astrocytes and precedes the expression of astrocyte markers such as GFAP and 
SPARCL1. Overexpression of NFI-X3 dramatically upregulates GFAP and SPARCL1 
expression in glioma cells, while the knockdown of NFI-X3 diminishes the expression of 
both GFAP and SPARCL1 in astrocytes. Although activation of astrocyte-specific genes 
involves DNA demethylation and subsequent increase of histone acetylation, the TA 
domain of NFI-X3 activates GFAP expression by inducing alteration in the +1 
nucleosome architecture that lead to the increased recruitment of RNA polymerase II. 
Thus, we propose that NFI-X3 is the major isoform of NFI-X regulating astrocyte 
specific gene expression during their differentiation, likely via nucleosomal remodeling 
of the astrocyte specific promoters. 
 NFI-X knock-out animals display severe neuroanatomical defects including 
partial agenesis of the corpus callosum and hydrocephalus, however the target genes of 
NFI-X in the CNS remained elusive. Here, we show for the first time that YKL-40 is a 
novel target gene of NFI-X in astrocytes and controls their migration. In addition, we 
report that YKL-40 expression is activated during mouse brain development and also 
during the differentiation of neural progenitors into astrocytes in vitro. In primary 
astrocytes, YKL-40 expression is controlled by nuclear factor I-X (NFI-X) and signal 
transducer and activator of transcription 3 (STAT3), which are known to regulate 
gliogenesis. Indeed, knock-down of NFI-X and STAT3 significantly reduced YKL-40 
expression in astrocytes, while overexpression of NFI-X3 (a splice isoform of NFI-X) 
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xviii 
dramatically induced YKL-40 expression in glioma cells. In addition, activation of 
STAT3 by oncostatin M induced YKL-40 expression in astrocytes. Interestingly, STAT3 
activated YKL-40 expression via its binding site located in the YKL-40 proximal 
promoter, whereas direct NFI-X binding had not been detected. Surprisingly, NFI-X and 
STAT3 physically interact and this complex likely regulates YKL-40 expression in 
astrocytes. We further show that NFI-X controls migration and invasion of astrocytes and 
glioma cells, respectively, by regulating YKL-40 expression. These novel data suggest 
that YKL-40 is expressed by astrocytes during brain development and controls astrocyte 
migration. 
 Since YKL-40 is used as a shared biomarker for ongoing inflammation and 
oncogenic transformation and its (high) levels correlate to the severity of disease, we 
have tested its expression in astrocytes and microglia (CNS macrophage) after treatment 
of various neuro-inflammatory cytokines. Here we report, that IL-1 and IL-6/OSM 
synergistically activate YKL-40 expression in astrocytes but not in microglia when added 
together. Furthermore, induced YKL-40 expression can be detected in the media from 
astrocytes but not from microglia. Since YKL-40 is a secreted molecule and is highly 
upregulated in CSF of multiple sclerosis patients, we have tested its role in 
oligodendrocyte differentiation. Preliminary observations clearly demonstrate that YKL-
40 inhibits myelin basic protein (MBP) expression during the in-vitro differentiation of 
oligodendrocyte progenitor cells into myelin producing oligodendrocytes. Thus, we 
propose that YKL-40 is produced and secreted by reactive astrocytes during various CNS 
pathologies, and may inhibit MBP expression in MS. 
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 In summary, these studies have identified novel mechanisms in astrocyte gene 
regulation and functions, and provided new insights into astrocyte biology, with the 
implications for further understanding of the development and progression of CNS 
pathology.    
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CHAPTER 1 
ITRODUCTIO 
1.1 Astrocytes 
Astrocytes are the ‘star’ shaped cells in the central nervous system (CNS). These 
are the major sub-type of glial cells, and comprise more than 50 percent of the total 
human brain cells. Evolutionarily, their morphology is conserved, suggesting their basic 
functions remain conserved as well. However, astrocytes in the human cerebral cortex are 
structurally much more complex than those of other mammals, and are believed to be 
taking part in the learning and memory processing of the organism [1].  
On the basis of morphology, antigenic phenotype and location, astrocytes can be 
categorized in two main types: Protoplasmic astrocytes, and Fibrous astrocytes. 
Protoplasmic astrocytes are found in grey matter and have many fine branched processes 
whose end termini ensheath synapses, the cell body of the neuron as well as blood vessels 
[2]. In contrast, fibrous astrocytes are mainly found in white matter and have long and 
thin unbranched processes, which closely associate with nodes of Ranvier (axons) and 
blood vessels. In addition, there are some specialized astrocytes namely Muller glia found 
in the retina, and Bergmann glia found in the cerebellum. Based on their location and 
antigenicity, these special glia can be considered as protoplasmic glia [1]. 
These cells were considered to be the space filling cells in the CNS with 
supportive functions to their excitable neighbors, the neurons. Closely spaced to neurons 
and with tight association to the endothelial cells of blood brain barrier, astrocytes 
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provide energy and substrates to neurons in a neuronal activity dependent manner. Thus, 
they can sense the active neurotransmission at the synapses and consequently dilate the 
blood brain barrier to allow the entry of more oxygen and glucose in the active brain 
region. During early brain development, astrocytes secrete factors that are critical for 
active synapse formation and also synapse elimination [2]. Astrocyte-secreted cholesterol 
strongly enhances the presynaptic functions; however, yet unidentified molecule(s) 
enhance postsynaptic function and astrocyte secreted thrombospondin (TSP) proteins 
induce retinal ganglion neurons to form synapses [3],[4]. Astrocytes can participate in 
synapse elimination by activating neurons and microglia to express and secret C1q 
complement [5].  
During embryonic brain development, radial glia (early astrocytes) acts as stem 
cells which can differentiate into neurons and oligodendrocytes [6, 7]. In addition, these 
radial glia cells provide a scaffold for proper neuronal migration and hence their 
appropriate location in the cerebral cortical region [8]. In addition, a subset of astrocytes 
in the subventricular zone (SVZ) give rise to olfactory neurons in vivo and are capable of 
forming clonal self-renewing mutipotent neurospheres [9]. Astrocytes secrete many 
developmentally-regulated tropic and trophic factors which support and help guide axons 
during early postnatal brain development. Interestingly, the expression of these factors is 
induced in reactive astrogliosis during/post injury or in pathological states of brain and 
thus are thought to help guide axon regeneration and reconnection [2] .  
Thus, there is no doubt that astrocytes, the most abundant cell type in the CNS, 
control many functions in the normal as well as pathological states of brain.  
 
 3 
1.2 Astrocytes in brain pathologies 
 Astrocytes are involved in almost all kinds of CNS pathologies. The most 
prominent feature of astrocytes associated with CNS insult/disease is the changes in their 
morphology, also known as reactive gliosis or astrogliosis, with complex, hypertrophic 
and extended processes. Reactive-gliosis mainly results from the activation of astrocytes 
by inflammatory cytokines released at the site of injury, infection or disease primarily by 
microglia, the immune cells of the CNS [10, 11].  
The dystrophic astrocytes/reactive astrocytes appear prior to the appearance of 
neuritic plaque, the most prominent feature of Alzheimer’s disease (AD) and also 
coincides with the distorted synaptic structures observed in mouse models of AD. This 
led us to speculate that astrocytes might play a direct critical role in AD progression. In 
accordance, application of anti-inflammatory drugs delays the AD progression [11]. 
However, all these observations are primarily associative and do not conclude the direct 
involvement of astrocytes in CNS pathologies.  
Direct involvement of astrocytes in disease progression can be attributed to the 
dominantly inherited/sporadic forms of various neurodegenerative disorders including, 
amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), RETT syndrome and the 
familial form of Parkinson`s disease (PD).  In the case of inherited ALS, an adult motor 
neuron disease, the loss of motor neurons is associated with missense mutations in the 
superoxide dismutase 1 (SOD1) gene. Interestingly, wild-type primary neurons when co-
cultured with the primary astrocytes from SOD1 mutant animals undergo cell death over 
a 2 week period of time. This neurotoxic effect from astrocytes is coming from the 
conditioned media of mutant astrocytes clearly demonstrating a direct role of astrocytes 
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in ALS progression [11, 12]. However, the identity of these neurotoxic soluble factors 
remains to be explored. 
RETT syndrome, a neurodevelopmental disorder, is caused due to the mutations 
in the gene methyl C binding protein 2 (MeCP2) located on the X- chromosome. Until 
recently, MeCP2 protein was believed to be expressed exclusively in neurons in the CNS 
and thus the disease was also thought to be exclusively neuronal. However, recently two 
groups have elegantly shown that MeCP2 is expressed in the glial cells also particularly 
in the astrocytes [13, 14]. In addition, they also demonstrated that normal neuronal 
cultures when grown in the conditioned media of mutant MeCP2 astrocytes have 
abnormal dendritic arbor with shorter and less number of branches, suggesting that 
astrocytes also contribute to the RETT syndrome progression at least in-part [13, 14]. The 
secretory/soluble factors from the mutant astrocytes remain to be identified. 
Similarly, familial form of PD is associated with the mutation in the gene NURR1 
which leads to low expression of Nurr1 protein, an orphan nuclear receptor. The 
mechanism of Nurr1 action in PD progression has recently been demonstrated by 
Michael Glass` group. This study shows that Nurr1 protein interferes with the 
transcriptional activity of NF-κB and represses NF-κB induced inflammation-associated 
neurotoxic factor expression. Furthermore, the inhibitory role of Nurr1 was only 
observed in astrocytes and microglial cells but not in neurons [15]. Thus in the absence of 
Nurr1 (as in the case of PD), microglia and astrocytes secrete soluble factors which are 
neurotoxic to neurons. 
Apart from the neurodegenerative disorders, some of the brain tumors known as 
astroglioma (glioma) are known to be of astrocytic origin and express the astroglial 
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marker gene GFAP. It is believed that, due to the oncogenic mutations, glioma cells exit 
the normal astrocytic differentiation process and gain the potential of unlimited cell 
division. In short astrocytes can be considered as the source of glioma [16]. 
Taken together from all the above examples it is clear that astrocytes actively and 
directly play roles in the progression of many neurological disorders. Thus astrocytes are 
now considered as novel cellular drug targets for therapeutic intervention of much 
neurological pathology. However, the identity of the soluble factors released by 
astrocytes and their precise mechanism of action in pathological states remains an open 
area of active research.  
 
1.3 Differentiation of astrocytes 
  The mammalian CNS is developed from the epithelial layer of the embryo named 
as neuro-epithelium, which comprises of mutipotent neural precursor cells (NPC). These 
NPCs generate neurons first (neurogenesis) from E12-E18, and glia second (gliogenesis). 
During the gliogenic phase, astrocytes are generated at around E18, with their numbers 
peaking in the neonatal period; oligodendrocytes are first seen postnataly. The data 
accumulated over the last decade or so suggest that several signaling pathways, including 
JAK-STAT pathway, SMADS, the Notch signaling and the Nuclear Factor-I (NFI) 
family of transcription factors, are crutial for astrocyte differentiation and hence the 
expression of astrocyte marker genes, including GFAP, SPARCL-1, GLAST, and S100B 
[17, 18]. In addition, epigenetic mechanisms also control gliogenesis as evidenced by the 
studies that during the early neurogenic phase most of the astrocyte-specific gene 
promoters are highly methylated and hence are repressed [47]. 
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 The pregenerated neurons from the NPCs are the prime suspects to induce 
astrocyte differentiation from the same NPCs, at the late gestation period. Accordingly, 
neuronal derived Cardiotrophin-1 (CT-1), an IL-6 cytokine family member that activates 
the gp130-JAK-STAT pathway, directs NPCs to differentiate into astrocytes at around 
day E13.5. During the same period, astrocyte-specific gene promoters are demethylated 
allowing STAT3 to bind to and activate the respective gene promoters [19]. In addition, 
the JAK-STAT pathway activates BMP-2 production and subsequent SMAD1 activation 
followed by its translocation into the nucleus. The activated SMAD1 then forms a 
complex with STAT3 bridged by p300/CBP co-activator [20] [25]. This complex binds to 
the promoters of glial specific genes such as GFAP to synergistically activate their 
transcription. 
 Recently, another group of transcription factors called the Nuclear factor-I (NFI) 
family has been reported to be necessary and sufficient for gliogenesis, as shown by the 
fact that the mis-expression of NFI-A factor leads to precocious expression of GLAST 
and GFAP genes in chick embryonic spinal cord [18]. In agreement, NFI-A and NFI-B 
knock out mice have severe brain defects including agenesis of corpus callosum, reduced 
number of GFAP positive astrocytes, and loss of midline-glial population [21, 22]. 
Recently, our lab has demonstrated that NFI-C and NFI-X factors are critical for late 
astrocyte marker gene expression in an in vitro model of astrocyte differentiation from 
human neural progenitors (NPs) [23]. It was also shown that NFI factors can inhibit 
neurogenesis indirectly by controlling the expression of the notch effector Hes5. Thus 
NFI factors can regulate the switch from neurogenesis to gliogenesis during the mid to 
late gestation period [18].  
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 Notch signaling which leads to the activation of transcription factor RBP-Jκ has 
also been implicated in gliogenesis; however this requires an active JAK-STAT pathway. 
Upon activation, notch signaling converts the RBP-Jk repressor complex into an activator 
complex. The RBP-Jk activator complex binds to notch effector gene promoters 
including Hes and Hesr (hes related proteins) which antagonizes proneural gene 
expression [24]. However, until recently it was not known how Notch, NFI, and JAK-
STAT factors precisely activate neurogenic to gliogenic switch. Elegant studies from 
Kinichi Nakashima`s group has recently shown that during the development of mid-
gestational telencephalon, Notch ligands are expressed on the committed neuronal 
precursors and young neurons and that the neighboring Notch-activated NPCs achieve 
the potential to differentiate into astrocytes [25]. More precisely, activation of Notch in 
NPCs induces the expression of NFI-A factor, which binds to astrocyte-specific gene 
promoters, leading to demethylation of astrocyte-specific genes, and subsequent de-
repression [25].  
 These studies, mainly from mouse brain development, have greatly increased our 
understanding of astrocyte differentiation process; however, the precise regulation and 
role of NFI factors in this process is still unclear.  
 
1.4 uclear Factor I 
 The phylogenetically conserved NFI family of transcription factors regulates the 
expression of various cellular and viral genes, together with adenoviral DNA replication. 
It comprises of four DNA-binding proteins: NFI-A, NFI-B, NFI-C, and NFI-X [26]. 
During mouse embryogenesis, they are expressed in complex, unique and overlapping 
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patterns. Their expression is developmentally regulated [27], suggesting that they may 
play distinct and important roles in tissue specific gene expression during mammalian 
embryogenesis. 
All four NFI isoforms are expressed in many tissues, with high levels of expression of 
NFI-A, NFI-B, and NFI-X transcripts in the developing neocortex [27]. Approximately, 
75,000 NFI binding sites are found in the human genome in-silico [26]; however only a 
few NFI binding sites have been characterized for cell or tissue specific genes, these 
include; astrocyte specific GFAP (Glial Fibrillary Acidic Protein), S100B [28, 29], radial 
glial specific B-FABP (Brain Fatty Acid Binding Protein) [30], and oligodendrocyte 
specific MBP (myelin basic protein) [31]. NFI binding sites have also been characterized 
for ubiquitously expressed genes, including p21
WAF1/CIP1
, tumor suppressor p53, and 
cyclin D1. Therefore, NFI proteins seem to be not only involved in development, but also 
in cellular differentiation and cell growth.     
Indeed, knockout studies have validated a functional role of NFI-A, NFI-B, and NFI-
X in the brain. Disruption of Nfia or Nfib causes late gestation neuroanatomical defects, 
including agenesis of corpus callosum, size reduction in other forebrain commissures, 
and loss of midline glial populations [21]. In addition, Nfib-deficient mice show aberrant 
hippocampus and pons formation, and defects in lung development [32], while Nfix-
deficient mice show severe skeletal defects with kyphosis, and brain defects, including 
hydrocephalus and ventricle enlargement [33]. In contrast, the disruption of Nfic results 
in early postnatal defects in tooth formation [34] 
NFI factors share a highly homologous, conserved 200-aa N-terminal DNA-
binding/dimerization domain that is also sufficient for adenoviral DNA replication in 
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vitro. NFIs can form homo or heterodimers and binds to the consensus DNA sequence 
TTGGC (N) 5GCCAA with almost equal efficiency. However, C-terminal transcriptional 
regulation domains of NFIs significantly differ with each other across species. In fact, 
frequent alternative splicing can create as many as nine protein products for each gene 
[26]. In addition, differential phosphorylation of NFIs in various cell types provide an 
extra layer of regulation of transcriptional activity [35].  
The NFI proteins have been implicated in both transcriptional activation and 
transcriptional repression, which are cell-, tissue-, and promoter- type specific. A number 
of different mechanisms are proposed to explain NFIs transcriptional activity. NFI-C was 
shown to activate transcription by its C-terminal proline rich transactivation domain 
through direct interaction with the basal transcription machinery. Infact, the proline rich 
domain of NFI-C contains a heptapeptide which is highly homologous to the C-terminal 
domain (CTD) of RNA-polymerase II [36]. In addition, deletion of the CTD like domain 
in NFI-C abolishes its interaction with human TFIIB [37] and yeast TBP [38], and hence 
transactivation. According to another proposed mechanism, NFI can activate gene 
transcription by simply removing the repressive histone H1 from the gene promoter [39]. 
In addition, the C-terminal proline rich domain of NFI-C has been shown to directly 
interact with histone H3 [26], and bind to co-activator proteins, including p300/CBP and 
Ski [26]. These data suggest that NFI-C can activate gene transcription by the 
simultaneous removal of the repressive histone H1 and by bringing the co-activator 
complexed with histone H3. The transcriptional repression of NFI includes activities such 
as competition between NFI and more potent trans-activators for binding at adjacent or 
overlapping sites. Competition between NFI and Sp1 has been proposed to repress the 
 10 
Sp1 activation of the mouse α1 (I) collagen promoter [40]. Moreover, the C-terminal 
transcription activation domain can bring repression in a cell-, promoter- type manner 
[41]. However, the splice isoforms of NFI-X present in CNS cells and their role during 
gliogenesis are not known. 
 
1.5 Gliomagenesis 
 Gliomas are one of the most common primary brain tumors [42]. According to 
W.H.O. criteria, gliomas can be divided into four grades based on their histological 
appearances; pilocytic astrocytoma, grade I; diffuse astrocytoma, grade II; anaplastic 
astrocytoma, grade III; and glioblastoma multiforme, grade IV [43]. Of these Grade III 
and grade IV tumors, also known as malignant gliomas, are the most aggressive [43]. 
Despite the common treatment procedures used for GBM, including surgery, radiation-
therapy, and chemotherapy, there is a poor prognosis for survival with a median patient 
survival between 9-12 months mainly due to their invasive nature. 
 Gliomas harbor a number of mutations in specific cellular transduction pathways 
including mutations in the p53 tumor suppressor activation pathway, EGFR/Ras 
activations, and PTEN mutation affecting PI3K-AKT pathway [43]. However, the exact 
cell of origin that leads to formation of gliomas is not known. Recent advances in brain 
tumor biology has identified stem like cells in gliomas thus supporting the notion that the 
bulk of the malignant cells in brain cancers are generated by relatively rare fractions of 
self renewing, multipotent, brain tumor initiating cells [44, 45]. These BTSCs express 
CD133 and nestin, which are the markers of NPCs [44]. In addition, BTSCs, similar to 
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NPCs, are radioresisatant [46], chemoresistant, and express higher levels of ABC 
transporters [47, 48] compared to their autologus CD133
- 
cells. In addition, it is known 
that glioma or tumor cells can utilize some of the normal functions of astrocytes in a 
deregulated way. It is apparent that understanding of the normal astrocytic differentiation 
process could lead to the better knowledge of understanding of gliomagenesis and 
perhaps novel therapeutic implementation to kill glioma cells specifically. 
    
1.6 IL-6 cytokine family and the JAK-STAT pathway 
Interleukin-6 (IL-6) family of cytokines including OSM, CNTF, LIF, and CT-1 is 
a group of potent, pleiotropic, inflammatory factors that mediates a number of redundant 
biological functions including cell survival, proliferation, migration, apoptosis, and 
development and differentiation [49]. Like other cytokines, this group facilitates its 
functions by binding to and heterodimerizing its receptors. Upon ligand binding the 
individual specific receptor subunit IL-6Rβ, LIFRβ, CNTFRβ, or OSMRβ 
heterodimerizes with a common gp130 receptor subunit. This leads to the activation of 
Janus kinases (Jak1, Jak2, Jak3 and Tyk2), the receptor associated tyrosine kinases, 
which phosphorylates tyrosine residue within the cytoplasmic domain of gp130 subunit 
and thus creating a docking site for Src-homology-2 domain containing proteins, 
including STATs. In the active receptor complex, STAT proteins are tyrosine 
phosphorylated which leads to their dimerization and subsequent translocation into the 
nucleus where it recognizes specific DNA elements in the promoter regions of target 
genes to activate transcription [49]. STATs can also be activated by many receptors with 
intrinsic receptor tyrosine kinase (RTKs) activity including EGF, and PDGF and non-
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RTKs, such as SRC [50-52]. There are seven known STAT proteins: STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b, and STAT6 [53]. Depending on the ligand type and 
the strength of its stimulus STATs can form homo/heterodimers. All except STAT2 can 
form homodimers. In-addition STAT1 and STAT2, and STAT1 and STAT3 can form 
heterodimers, and several STATs can form tetramers or even higher order structures [53, 
54]. Like other transcription factors, STATs too have a DNA binding, a dimerization and 
a transcriptional activation domain. Various post-translational modifications including 
acetylation, phosphorylation, sumoylation, and ubiquitination also have been shown to 
regulate its transcriptional activity and biological response. Particularly, serine 727 
phosphorylation within the transactivation domain of STAT1 and STAT3 enhances their 
transcriptional activity without affecting their DNA binding properties. Nuclear export of 
STAT proteins is favored once the phosphorylation mark is removed by nuclear 
phosphatases, such as TC45 in the case of STAT1 and STAT3 [55].  
In agreement with its role in regulating a plethora of physiological functions, 
JAK-STAT signaling is under tight control of negative regulation at different levels. 
There are several cytoplasmic tyrosine phosphatases including SH2-containing 
phosphatases 1 (SHP-1), SHP-2 and protein tyrosine phosphatases 1B (PTP1B) that 
dephosphorylate receptor and kinase phosphorylation sites thus disabling the recruitment 
of SH2 domain containing proteins including STATs [56, 57]. Another group of 
cytoplasmic inhibitors are the suppressors of cytokine signaling (SOCS) proteins, which 
bind to the receptor sites and/or Jak catalytic sites to block further STAT activation. 
These cytokine induced molecules can also drive protein turn over of the receptor and 
associated molecules by ubiquitin-proteasome mediated degradation [58]. In addition, 
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there are a few negative regulators of JAK-STAT signaling within the nucleus, such as 
protein inhibitors of activated stats 1 (PIAS1) and PIAS3. PIAS1 and PIAS3 interacts 
with tyrosine phosphorylated STAT1 and STAT3, respectively, and block their DNA 
binding in vitro [53].  
 
1.7 IL-1 cytokine and its downstream signaling 
 Interleukin-1 (IL-1) is the predominant pro-inflammatory cytokine associated 
with the host-defense response to injury and infection [59]. It is an important mediator of 
both acute and chronic CNS disorders including brain trauma, stroke, epilepsy, AD and 
PD [60] [11]. The most characterized isoforms of IL-1 are IL-1α and IL-1β. Both of them 
act as agonists and binds to the same type I receptor (IL-1R1), which then associates with 
an accessory protein (IL-1R1AcP) to activate the downstream signaling cascades [61, 
62]. Furthermore, this signaling leads to the production of secondary inflammatory 
mediators such as cytokines, chemokines and prostaglandins. There is a naturally 
occurring IL-1R antagonist (IL-1Ra) , which is soluble in nature and competes with IL-
1R as well as acts as a buffering agent for the excess of IL-1 to inhibit downstream 
signaling [59, 62, 63].  
The level of IL-1 expression in normal healthy individuals is very low. However, 
its expression dramatically increases in reply to the injury/infection [59]. In CNS 
activated microglia are the major contributor for IL-1 production. Soluble factors released 
by activated microglia then can stimulate astrocytes, oligodendrocytes and even neurons 
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for the further production of IL-1 [11, 64-66]. All the cell types of the CNS except 
microglia express IL-1R1 and therefore respond to IL-1 [59].  
Upon binding to its receptor, IL-1 can activate various signaling cascades, mainly 
the activation of the IKK-NFκB pathway and the mitogen-activated protein kinases 
(MAPKs) p38 MAPK, JNK and ERK1/2 in astrocytes [67]. This activation is followed 
by increased cell proliferation and hypertrophic changes in morphology also known as 
reactive astrogliosis. In addition, IL-1 activated astrocytes produce VEGF and many 
other factors important for angiogenesis, vessel plasticity and astrocyte migration which 
are critical for recovery and repair of injury site within the brain [68]. Oligodendrocytes 
can also respond to IL-1 treatment. However, IL-1 does not induce their proliferation 
rather it promotes oligodendrocyte differentiation and maturation, indicating that it might 
affect the re-myelination and repair process after injury [59, 69].  
In neurons, low levels of IL-1 expression are considered to regulate normal 
physiological functions including sleep, memory and long term potentiation. Effect of IL-
1 on neurons depends on the IL-1 concentration and the duration of the activation. In 
neurons, IL-1 does not signal through MAPK, JNK and ERK1/2 activation; rather, it 
activates Src kinase [70, 71]. Furthermore, the low concentration of IL-1 makes neurons 
more vulnerable to neurotoxic effects from glial cells. Both glia and neurons produce 
various neuro-trophic and growth factors in response to high concentrations of IL-1 that 
promote neuronal survival [72]. At the molecular level, a high concentration of IL-1 
activates the c-Rel subunit of NF-κB instead of Rel-A and, hence, is responsible for its 
protective effects [73]. 
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In vivo, deletion of IL-1α/β gene in mice greatly reduces ischemic brain injury. In 
contrast, deletion of IL-1Ra (the antagonist) increases ischemic brain injury by 3 fold and 
causes increased mortality [62]. 
Clearly, IL-1 plays a profound role in response to CNS injury/infection. It is 
intriguing that it can have neurotoxic as well as neuroprotective effects depending on its 
concentration and the duration of its presence in the injured area. It will be interesting to 
explore the genes/factors responsible for its contradicting role on neurons. 
 
1.8 CS inflammation 
 Until recently, the CNS was considered to be an ‘immune privileged’ organ, and 
to be not susceptible to inflammation. The immune cells constantly flowing in the blood 
stream and surveying the injury, infection or a disease state in the various organs/ tissues 
have limited access to the CNS due to the tight and impermeable nature of the blood 
brain barrier (BBB). However, the CNS has its own resident immune cells known as 
microglia which are of hematopoietic origin and considered to be similar to macrophages. 
During early embryonic brain development, precursors of microglial cells enter into the 
nervous tissue before BBB is formed [74]. The microglial cells are able to sense the very 
minute changes in the local environment and respond to any injury, infection or 
pathological state by secreting pro-inflammatory cytokines including IL-1, TNFα, and 
IL-6. Subsequently, activation of astrocytes and microglia leads to further production of 
these cytokines and secondary inflammatory mediators including prostaglandins, free 
radicals and complement. In turn these mediators induce expression of many chemokines 
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and cell adhesion molecules which help recruit immune cells such as leukocytes through 
the BBB into the CNS [62].  
Almost all the CNS pathologies have an inflammatory component. The activated 
immune cells can produce many factors, including BDNF, which are otherwise 
exclusively produced by the CNS cells and thus establish a cross-talk with the CNS cells 
during inflammation. Similarly, CNS cells, mainly reactive astrocytes, can also produce 
many inflammatory mediators and cytokines which would help immune cells such as B 
cells proliferate within the CNS. Thus the nature of this cross-talk between CNS cells and 
immune cells during CNS inflammation is intricate [75]. The question is if the 
inflammation in CNS pathologies is beneficial or harmful? Not surprisingly, 
inflammatory mediators have dual roles, with deleterious effect in the acute phase and 
beneficial effect in long term repair and recovery phase of the CNS pathologies. The 
proinflammatory and neurotoxic factors include Th1 type cytokines, IL1, TNF, reactive 
oxygen species etc. However, the anti-inflammatory and neuroprotective factors of CNS 
inflammation include Th2 type cytokines, IL-1ra, sIL-1R, BDNF, GDNF, LIF etc [11, 
75, 76].  
Acute CNS injuries including stroke, brain trauma and epilepsy are characterized 
by increased levels of expression of pro-inflammatory mediators IL-1, TNFα, IL-6 and 
free radicals and are deleterious in nature. Therapeutic use of antagonists or inhibitors of 
these pro-inflammatory cytokines’ administration to acute CNS injury has a beneficial 
outcome with less severe pathology in animal models [62].  
Chronic CNS diseases including multiple sclerosis (MS), AD, PD and 
schizophrenia are also characterized by active inflammation within the pathological 
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areas. Moreover, increased expression of proinflammatory cytokines including IL-1, IL-6 
and TNFα is observed in these pathologies. Microarray analysis performed on 
pathological brain samples from MS, AD and PD has revealed that enriched levels of 
mRNA of many other inflammation associated genes, indicating an active ongoing 
inflammation within these neurodegenerative diseases. The application of anti-
inflammatory drugs in animal models of these conditions improves disease pathology, 
supporting the idea that ongoing inflammation actively participates in the chronic CNS 
disease progression [62].  
Presence of the reactive astrocytes is another hallmark of CNS inflammation. 
They not only produce many inflammatory mediators, chemokines, and angiogenic 
factors but also form a physical barrier by forming gliotic scar surrounding the inflamed 
area. The gliotic scar inhibits axon regeneration during repair phase, suggesting a harmful 
role for reactive astrocytes in the CNS inflammation/injury. However, when reactive 
astrocytes were ablated in a transgenic animal, more neuronal cell death was observed 
upon injury/insult [77]. This demonstrates that reactive astrocytes, despite acting as 
physical barrier, provide neuronal support in the inflamed/injured area by producing 
many neuro-trophic factors such as BDNF and GDNF. They also secret thrombospondins 
which are involved in synapse formation, thus helping synapse regeneration after injury 
[78]. 
Thus, it is quite evident that inflammation associated with CNS actively plays a 
crucial role in CNS disease progression. Indeed, targeting CNS inflammation is  
considered as therapy for CNS diseases. But, we have to be cautious of the fact that 
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inflammation has dual role to play in CNS pathologies. Therefore the identities of the 
dual nature of inflammation need to be addressed in order to design new therapies.  
 
1.9 Inflammation associated with cancer 
The link between cancer and inflammation has been made by epidemiological 
studies that suggest chronic inflammation predisposes individuals to many types of 
cancers. It is also observed that non-steroidal anti inflammatory drugs reduce the risk of 
developing certain type of cancers including colon and breast cancer and reduces the 
mortality rate caused by these tumors. Inflammatory cells and inflammatory mediators 
are found in almost all types of cancer microenvironment from human tumor biopsies. 
Thus inflammation is associated with cancer incidence and actively promotes tumor 
progression [79]. The expression of the pro-inflammatory cytokines including IL-1, IL-6, 
OSM, TNFα and prostaglandins are highly upregulated in cancer associated 
inflammatory cells as well as within cancer cells [80-82]. Targeting cancer associated 
inflammation for drug therapeutics might synergistically act together with the 
conventional drugs used for cancer therapy. 
Two distinct pathways can be drawn in order to link inflammation and cancer: in 
the extrinsic pathway, chronic inflammatory condition increases the risk of cancer 
development (for e.g. inflammatory bowel disease) and in the intrinsic pathway, genetic 
mutations in oncogenes causes inflammation and tumor development. Despite two 
different modes of association, both pathways ultimately activate the same downstream 
inflammation associated transcription factors NF-κB and STAT3 [79]. Because of the 
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ability of NF-κB to induce many inflammatory mediators and to play a pivotal role in the 
normal infection-driven immune response, NF-κB is regarded as the major player in 
inflammation-induced tumorigenesis and anti-tumor immunity. In accordance, 
constitutively active form of NF-κB complexes has been observed in many forms of 
malignant tumors [54]. The repertoire of genes regulated by NF-κB falls in the category 
of pro-survival, anti-apoptotic, angiogenic and metastatic functions, which are hallmarks 
of tumor associated inflammation. Some of the factors downstream of NF-κB are IL-6, 
TNFα, IL-1, and COX-2 etc which can further activate inflammation associated gene 
expression in an autocrine and paracrine fashion. Apart from its role in tumor progression 
NF-κB can also drive T-cell mediated anti-tumor immunity by upregulating Th1 type 
cytokines such as IL-12 and interferon-γ (IFNγ) [54, 79]. It is intriguing how NF-κB 
serves as a regulator of cancer promoting and cancer inhibitory gene expression at the 
molecular level. The NF-κB family consists of RELA, REL, RELB, p50 and p52 
members. Among these only RELA, REL and RELB possesses a transcriptional 
activation domain. The RELA-p50 heterodimer is the most general NF-κB transcription 
factor, which is critical for expression of pro-inflammatory genes including IL-1, IL-6, 
IL-23 and COX2 which can also serve as cancer promoting factors. In contrast, the REL-
p50 heterodimer mainly activates gene expression of T helper type 1 (Th1) cytokines 
such as IL-12 and IFNγ. It is also noteworthy that, within the tumor cells, only RELA but 
not REL is constitutively activated implying that somehow cancer cells utilize pro-
carcinogenic functions and at the same time escape the anti-tumor immunity posed by 
NF-κB activation.  
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The family of STAT transcription factors controls immune responses within the 
tumor microenvironment. Particularly STAT1 activation leads to production of IL-12 
which induces production of IFNγ, a Th1 type cytokine, that subsequently activate 
cytolytic activity of macrophages, natural killer cells and CD8+ T cells [53]. In contrast, 
constitutively activated STAT3 is the major cancer promoting and inflammation 
associated transcription factor, which increases tumor cell proliferation, survival, 
metastatic invasion and also suppresses anti-tumor immunity. At the same time STAT3 
also mediates tumor promoting inflammation. In agreement with this, constitutively 
active STAT3 is present in almost all cancer types. The major inducer of STAT3 
signaling are the IL-6 type family cytokines including IL-6, LIF, OSM, IL-10 and IL-23 
[54]. In addition, STAT3 can also be activated by many growth factor receptors and 
associated tyrosine kinases for eg. EGFR, PDGFR, and SRC [83, 84]. All of these 
tyrosine kinases have been found to be either mutated or over-expressed and hence are 
constitutively active in many type of cancers leading to persistent activation of STAT3. 
The genes regulated by STAT3 can be categorized into anti-apoptotic, pro-proliferative, 
angiogenic, metastatic and Th17 type cytokines based on their functions. The inhibition 
of anti-tumor immune response of STAT3 comes by virtue of the fact that it can interact 
and thus inhibit STAT1 and NF-κB regulated Th1 type cytokine gene expression [85, 
86]. The cancer promoting function of STAT3 can be rendered to its regulation of many 
proinflammatory cytokines gene expression including IL-6, IL-1, MCSF, and COX-2. 
These proinflammatory cytokines released by tumor cells, harboring constitutive active 
STAT3, can act in a paracrine way to stimulate stromal cells in the tumor 
microenvironment, thus establishing a feed forward loop between tumor cells and the 
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immune cells in the microenvironment [86]. The importance of STAT3 in tumorigenesis 
is strongly demonstrated by the finding that, in the absence of Stat3 alleles, carcinogens 
were able to induce inflammation but not tumor incidence [87]. 
Given the crutial role of NF-κB and STAT3 factors in cancer-associated 
inflammation, it is not surprising that both the factors can interact with each other at 
multiple levels to further enhance the cancer promoting effect. In many cancers both the 
factors are constitutively activated within the same cells [87]. Both factors induce the 
expression of highly overlapping repertoire of proliferative, anti-apoptotic, angiogenic 
and metastatic genes [79, 87]. Constitutive activation of nuclear NF-κB requires its 
acetylation by p300, which itself requires STAT3. Many NF-κB activated genes 
including IL-6 and IL-23 are also activator of STAT3 signaling. In contrast to the above 
similarity, STAT3 opposes the anti-tumor immunity activated by NF-kB. REL-p50 NF-
κB complex specifically regulates Th-1 immunostimulatory genes which possesses anti-
tumor immunomodulatory effect [49]. Persistently activated STAT3 down-regulates the 
expression of REL subunit, thus diminishing its anti-tumor effect, allowing tumor to 
progress [88].  
Like many other tumors, STAT3 and NF-κB factors are constitutively activated in 
almost all human glioblastoma multiforme (GBM) tissue, the most aggressive form of 
brain tumor. Furthermore, GBMs have higher expression levels of IL-6 and OSM leading 
to constant activation of STAT3 signaling [89]. The deregulation of the expression of 
many growth factor receptors and their mutation can also lead to activation of STAT3 
and NF-κB. 
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1.10 Chitinase 3-like 1 (CHI3L1) or YKL-40 
 YKL-40 is a secreted 40 kDa glycoprotein. It is also known as human cartilage 
glycoprotein-39 (HC gp-39), Chitinase 3-like protein-1 (CHI3L1), the mouse homologue 
breast regression protein-39 (BRP-39), and chondrex. The gene for YKL-40 is located on 
chromosome 1q31-q32 in human. Based on crystal structure homology YKL-40 belongs 
to glycohydrolase family 18, which is comprised of many bacterial and eukaryotic 
proteins with chitinase activity [90] [91]. The YKL-40 protein has 383 amino acids and is 
synthesized with an 8 amino acid N-terminal pro-peptide sequence which is cleaved 
before the protein gets secreted. Due to a single amino acid substitution of glutamate to 
leucine in its core chitinase binding pocket, YKL-40 is an enzymatically inactive protein, 
though it still binds to chitin and many other carbohydrate molecules [91].  
In normal individuals the major source of YKL-40 levels are activated 
macrophages, neutrophils, activated chondrocytes, synoviocytes and smooth muscle cells 
[91]. It is also highly upregulated during the differentiation of monocytes to 
macrophages, and smooth muscle cell differentiation [92]. However, expression of YKL-
40 has been found to be highly upregulated in most of the pathologies associated with 
ongoing inflammation, tissue remodeling and cancers such as rheumatoid arthritis, 
osteoarthritis, asthma, breast cancer cells, Glioblastomas, papilliary thyroid carcinomas, 
and extraskeletal myxoid chondrosarcoma, colon cancer, melanoma and metastatic 
prostrate cancer. Furthermore, a high level of YKL-40 expression is also correlated with 
the disease severity and the high mortality rates of various pathological states, including 
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GBM. In agreement, YKL-40 expression increases on stimulation with proinflammatory 
cytokines in the macrophages and many other cell types including chondrocytes, and 
cancer cells [91, 93]. Moreover, mice lacking YKL-40 gene showed impaired antigen 
induced Th2 responses, with YKL-40 being a potent inhibitor of death-receptor induced 
inflammatory cell apoptosis. The expression of IL-4 and IL-13 level was decreased in 
YKL-40 null animals challenged with antigen compared to the sham-treated animals [94].  
Despite its high level of expression in almost every pathology, regulation of its 
expression and the functions of YKL-40 remain poorly defined. Analysis of the -1.3 kb 
upstream region of YKL-40 promoter revealed presence of several transcription factor 
binding sites including, AP-1, CEBP, Sp1, Sp3, NF-kB and ETS [92]. Moreover, during 
monocyte to macrophage differentiation expression of YKL-40 is mainly controlled by 
the SP-1 transcription factor [92]. In response to proinflammatory cytokines IL-1 and 
TNFα, expression of YKL-40 is regulated by NF-κB transcription factor in chondrocytes 
[93]. However, cell and tissue specific expression of YKL-40 can not be ruled out as, IL-
1 and TNFα represses YKL-40 expression in glioma cells [95]. In addition, the level of 
YKL-40 expression increases upon stress stimuli including, hypoxia, cell confluence, 
serum starvation, and genotoxic stress (UV irradiation) in glioma cells [96]. However, 
hypoxia induced expression of YKL-40 was independent of the HIF-1 transcription factor 
[96].  
There have been few studies demonstrating functions of YKL-40. It can work as a 
mitogenic factor for several cell types including skin and lung fibroblasts, chondrocytes 
and synovial cells. It also act as a pro-survival factor when cells are exposed to stress 
conditions [91]. Moreover, primary transformed astrocytes overexpressing YKL-40 are 
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resistant to irradiation treatment [97]. In addition, YKL-40 can also serve as chemotactic 
factor for HUVECs, and as adhesion and migration factor for vascular smooth muscle 
cells. Indeed, its overexpression significantly increases migration of transformed 
astrocytes [97]. Thus, in general, YKL-40 appears to function as a tissue remodeling, pro-
survival, and pro-growth factor. In agreement to its pro-survival and pro-growth 
functions, YKL-40 has been shown to activate MAPK/ERK1/2 and PI3K/AKT signaling 
when added exogenously [98, 99]. However, the precise mechanism of this activation is 
not known. Since, YKL-40 protein contains a heparan binding motif it has recently been 
shown that YKL-40 can bind to syndecan-1 (receptor for heparan sulfate binding protein) 
and which further enhances its association with avb3 intergrin. This complex formation 
leads to the phosphorylation and activation of FAK, and subsequent activation of ERK1/2 
and PI3K [98]. It is also noteworthy that most of the growth factors, including FGF, 
PDGF, and EGF require syndecan proteins in order to bind to and activate their specific 
receptors [100, 101]. Likewise we may speculate that YKL-40 have a specific 
unidentified receptor and can function like many other growth factors. It may also 
compete with the growth factor binding with syndecans. In agreement, YKL-40 has been 
shown to replace bound bFGF from heparan sulfate columns, and thus could negate 
functions of bFGF, as shown in hippocampal neuronal cultures [102].   
Gene profiling and CSF protein profiling experiments done on patients associated 
with several CNS pathological states including schizophrenia, Alzheimer’s disease, 
Parkinson`s disease, multiple sclerosis, RETT syndrome, and glioblastoma have provided 
evidence that expression of YKL-40 is high in CNS pathologies [97, 103, 104]. However, 
the regulation and role of YKL-40 in CNS cell types remains elusive. Recently, it is 
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shown that increased expression of YKL-40 is associated with the increase in CSF viral 
load in SIVE. This increased YKL-40 expression was found in association with the 
microglial nodules in SIVE [102]. They further demonstrated that, in vivo YKL-40 
protein was deposited around astrocytes. However, in an in vitro culture only 
macrophages and microglial cells but not neurons and astrocytes could produce YKL-40. 
It was also shown that YKL-40 induces inhibition of axonal branching induced by bFGF 
by replacing bFGF from extracellular matrix [102]. Thus it is clear that regulation of its 
expression and function of YKL-40 during normal brain development as well as in 
various CNS pathologies remains open for further analysis.  
 
1.11 Hypothesis/Aim: 
 Since, NFI-X play critical role in normal mouse brain development, and is known 
to have several splice isoforms. We hypothesize that different splice isoforms of NFI-X 
might have different effects on normal astrocyte gene regulation and function. 
Furthermore, glioma cells, which are thought to be derived from astrocytes, could utilize 
the differential functions of NFI-X isoform regulated genes into their advantage to form 
aggressive tumors.  
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CHAPTER 2 
THE UIQUE TRASCRIPTIOAL ACTIVATIO 
DOMAI OF THE UCLEAR FACTOR-I-X3 IS CRITICAL 
TO SPECIFICALLY IDUCE MARKER GEE 
EXPRESSIO I ASTROCYTYES 
 
2.1 ABSTRACT 
Transcription factors of the Nuclear Factor 1 (NFI) family regulate normal brain 
development in vertebrates. However, multiple splice variants of four NFI isoforms exist, 
and their biological functions have yet to be elucidated. Here, we cloned and analyzed 
human NFI-X3, a novel splice variant of the nfix gene, which contains a unique 
transcriptional activation (TA) domain completely conserved in primates. In contrast to 
the previously cloned NFI-X1, overexpression of NFI-X3 potently activates NFI 
reporters, including a GFAP reporter construct, in astrocytes and glioma cells. The GAL4 
fusion protein containing the TA domain of NFI-X3 strongly activates the GAL4 
reporter, while the TA domain of NFI-X1 is ineffective. The expression of NFI-X3 is 
dramatically upregulated during the differentiation of neural progenitors to astrocytes and 
precedes the expression of astrocyte markers such as GFAP and SPARCL1. 
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Overexpression of NFI-X3 dramatically upregulates GFAP and SPARCL1 expression in 
glioma cells, while the knockdown of NFI-X3 diminishes the expression of both GFAP 
and SPARCL1 in astrocytes. Although the activation of astrocyte-specific genes involves 
DNA demethylation and subsequent increase of histone acetylation, the TA domain of 
NFI-X3 activates GFAP expression by inducing alteration in the +1 nucleosome 
architecture that lead to the increased recruitment of RNA polymerase II.  
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2.2 ITRODUCTIO 
Astrocytes are critical for the normal functions of the brain but also play a destructive 
role in many diseases of the central nervous system. Nevertheless, mechanisms 
controlling their differentiation and astrocyte-specific gene expression are only partially 
understood.  Astrocyte differentiation is promoted by the activation of several signaling 
pathways, including the JAK-STAT pathway [17, 105, 106], the activation of SMADs 
[106, 107], the activation of Notch signaling [108, 109], and the activation of genes 
encoding the Nuclear Factor-1 (NFI) family of transcription factors [25, 32, 35, 110-113].  
During vertebrate embryonic development, neurons are generated first, followed by glia.  
This neurogenic-to-gliogenic switch is induced by the activation of the JAK-STAT 
signaling pathway in neural precursors by neuron-derived cardiotrophin-1 (CT-1) [17].  
Specifically, STAT3 induces production of BMP-2, which subsequently activates 
SMAD1 [106]. In turn, SMAD1 forms a complex with STAT3 and induces 
astrogliogenesis [114].  In addition to JAK-STAT and BMP-SMAD1 pathways, Notch 
signaling also affects gliogenesis by activation of RBP-Jκ transcriptional activity [20, 
109], the induction of the NFI expression [25], and concomitant demethylation of the 
astrocyte-specific regulatory elements [25].  
The NFI family of transcription factors has recently emerged as important regulators 
of gliogenesis [22, 25, 26]. These proteins, encoded by four genes highly conserved from 
chickens to humans (fia, fib, fic, fix), regulate the transcription of various cellular 
and viral genes, as well as viral DNA replication [26, 115].  In vertebrates, products of 
these genes (NFI-A, -B, -C, and -X) share conserved N-terminal DNA binding and 
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dimerization domains, followed by a subtype specific domain, and a variable C-terminal 
transactivation domains [116].   
In mammals, the NFI genes are expressed in overlapping patterns during 
embryogenesis, with high levels of expression of NFI-A, -B, and -X in the developing 
neocortex [27].  The fia and fib knockout mice are characterized by neuroanatomical 
defects, including agenesis of the corpus callosum, loss of specific midline glial 
populations, and a 5-10 fold decrease in the expression of glial fibrillary acidic protein 
(GFAP), which is an astrocyte marker [21, 32, 113].  In addition, fib-deficient mice 
present aberrant hippocampus and pons formation, and die due to the defects in lung 
development [32].  The immature nestin-positive glia populate the hippocampus of fib-
deficient mice, but fail to mature into GFAP-positive astrocytes [117]. In contrast, 
disruption of the fic gene results in early postnatal defects in tooth formation, including 
the loss of molar roots and aberrant incisor development [34].  The fix knockout mice 
have recently been generated by two independent groups [118, 119], who reported 
multiple effects [120].  The fix gene knockout causes postnatal lethality in most of the 
animals, and leads to hydrocephalus and partial agenesis of the corpus callosum [118].  
These mice also develop a deformation of the spine with kyphosis, due to a delay in 
ossification of vertebral bodies and a progressive degeneration of intervertebral disks.  
However, fix knockout mice survive on a soft chow diet, but are characterized by 
increased brain weight, expansion of the brain along the dorsal ventricle axis, and 
aberrant formation of the hippocampus [119]. The knock-out phenotypes suggest that 
NFI-A, -B, and -X are important for normal brain development; however, the identity of 
the affected cell type(s) is not clear.  Recently, both NFI-A and -B were shown to 
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regulate gliogenesis in the chick embryo, with NFI-A also controlling the maintenance of 
neural precursors [18].  More recently, NFI-C and -X were shown to regulate the 
expression of late astrocyte markers during the differentiation of neural precursors into 
astrocytes in vitro [121]. 
Alternative splicing is a common mechanism of generating transcription factors with 
diverse functions in the brain [122-125]. Accordingly, transcripts of all four NFI genes 
are alternatively spliced, yielding many different proteins from a single gene [126, 127] 
with several different splice variants of NFI-X identified in human cells [128].  Here, we 
cloned and characterized a novel human NFI-X splice variant X3 (NFI-X3), which 
regulates gene expression in primary human astrocytes. This splice variant contains a 
unique transcriptional activation (TA) domain that is remarkably conserved in mammals, 
including mice, rat, dog, macaques, and humans. Mechanistically, the TA domain of NFI-
X3 activates GFAP expression by inducing structural alteration at the +1 nucleosome 
positioned at the GFAP transcription start site, and thus increasing PolII occupancy at this 
promoter.  
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2.3 MATERIALS AD METHODS 
2.3.1 Cell culture.  Human BG01V embryonic stem cells (ATCC, Rockville, MD) were 
cultured on mitomycin C-inactivated mouse embryonic fibroblast (MEF) layer. Cells 
were cultured in DMEM/F12 medium, supplemented with 20% knockout serum 
replacement (Gibco, Grand Island, NY), 1 mM L-glutamine, 0.1 mM nonessential amino 
acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 4 ng/ml basic fibroblast growth factor 
(bFGF) (PeproTech, Rocky Hill, NJ), and 0.1 mM β-mercaptoethanol. Cells were 
propagated in 4 day cycles, and enzymatically passaged with collagenase and trypsin. 
Human cortical astrocyte cultures were established using dissociated human cerebral 
tissue as previously described [129]. Cortical tissue was provided by Advanced 
Bioscience Resources (Alameda, CA), and the protocol for obtaining postmortem fetal 
neural tissue complied with the federal guidelines for fetal research and with the 
Uniformed Anatomical Gift Act. Human glioblastoma U373-MG cells and human 
embryonic kidney
 
HEK293 cells were obtained from American Type Culture Collection 
(Rockville, MD) while human glioma U87, U251, D54, and T98G cells were obtained 
from Dr. Jaharul Haque (Cleveland Clinic Foundation, Cleveland, OH).  Cells were 
cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf 
serum, antibiotics, sodium pyruvate, and non-essential amino acids. 
 
2.3.2 Generation of neural progenitors.  BG01V neural progenitors were generated as 
described previously [121]. Briefly, cells were grown in DMEM/F12, supplemented with 
15% defined FBS (Hyclone, Logan, UT), 5% KSR, 2 mM L-glutamine, 0.1 mM 
nonessential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 4 ng/ml bFGF, and 
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10 ng/ml leukemia inhibitory factor (LIF) (Chemicon, Temecula, CA). Subsequently, 
cells were grown for 7 days in differentiation medium composed of DMEM/F12, N2 
supplement (Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml 
streptomycin, and 4 ng/ml bFGF. Subsequently, the MEF layer was removed and cells 
were dissociated by DPBS without calcium and magnesium, followed by collagenase and 
trypsin incubation. Cells were then plated on laminin and poly-L-ornithin coated dishes, 
propagated in NB27 medium consisting of neurobasal medium, B27 supplement (both 
from Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml penicilin, 50 µg/ml 
streptomycin, 20 ng/ml bFGF, and 10 ng/ml LIF. Cells were maintained by passaging 
using trypsin.  
 
2.3.3 Differentiation into astrocytes. To generate astrocytes, neural progenitors were 
cultured on laminin and poly-L-ornithine coated dishes in DMEM, supplemented with 
10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, and 
nonessential amino acids for 21-24 days.  
2.3.4 Down-regulation of target genes. Expression of NFI-X mRNAs was down-
regulated using SmartPool siRNAs (si-panNFI-X) from
 
Dharmacon (Dharmacon, Int., 
Lafayette, CO). The NFI-X3-specific siRNAs (si-NFI-X3) was designed (Software 
provided on Dharmacon’s Website) to specifically target mRNA encoded by exon 9 (5’-
UCCUAUG CCUGAUUCCAAAUU-3’).  siRNA was transfected into astrocytes using 
Dharmafect 1, according to the manufacturer’s instructions.  
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2.3.5 RA isolation and quantitative PCR. Total cellular RNA was prepared by Trizol 
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol. Subsequently, 1 µg of 
total RNA was reverse-transcribed using the High Capacity cDNA Archive kit (Applied 
Biosystems, Foster City, CA).  GFAP, SPARCL1, NFI-X, and GAPDH mRNA levels 
were measured using pre-mixed primer-probe sets, and TaqMan Universal PCR Master 
Mix according to the supplier’s instructions (Applied Biosystems, Foster City, CA). The 
cDNAs were diluted 10-fold (for the target genes) or 100-fold (for GAPDH), and 
amplified using the ABI 7900HT cycler. Gene expression levels were normalized to 
GAPDH mRNA levels, and presented as a fold induction with mean values +/- standard 
deviation. Statistical analysis was performed by one-way analysis of variance. 
Differences were considered statistically significant when p-values were <0.05. The 
expression of NFI-X3 splice isoform was analyzed using the Power SYBRGreen PCR kit  
(Applied Biosystems, Foster City, CA) and the following primers: 5’-GTCGCTCGAGT 
CAGAGGAACCAGGACTG-3’ and 5’-GGTAGCGGCCAGGGCAAAG-3’ (the exon 9 
specific primer). 
 
2.3.6 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium 
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 
mM PMSF, and protease inhibitor cocktail (Roche, Mannheim, Germany).  Samples were 
resolved using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher 
& Schuell, Keene, NH). The anti-NFI, anti-GFAP, and anti-β-tubulin antibodies were 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), while anti-SPARCL1 antibodies 
were purchased from R&D Systems (Minneapolis, MN). Antigen-antibody complexes 
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were visualized by enhanced chemiluminescence using Immobilon Western blotting kit 
(Millipore, Temecula, CA). 
 
2.3.7 Synthetic oligonucleotides.  The following oligonucleotides were synthesized to 
amplify the NFI-X1 from the astrocyte cDNA: 5’-
CGGAAGCTTCGCCATGTACTCCCCGTACTGCC-3’ and 5’-
TGTGCTCGAGTCAGAAAGTTGCCGTCCCG-3’. The NFI-X3 was amplified in two 
steps to avoid the amplification of NFI-X1, which is the major splice isoform. The N-
terminal part of NFI-X3 was amplified with the following primers: 5’-
GTGAAGCTTCGCCATGGATGAGTTCCACCCGTTC-3’ and 5’-GGTGATGGAGGA 
GTCAAG-3’, while the C-terminus was amplified with 5’-GGTGCGGCCAGGGCAAA 
G-3’ and 5’-GTCGCTCGAGTCAGAGGAACCAGGACTG-3’.  Subsequently, both 
PCR products were combined, and the full length NFI-X3 was amplified with the primers 
containing the HindIII and XhoI sites (underlined above). The transactivation domains of 
NFI-X1 and NFI-X3 were amplified using the following primers: 5’-AGGGGATCCTG 
AAGGAGTTTGTGCAGTTT-3’ and 5’-GTGTCTAGATCAGAAAGTTGCCGTC-3’ 
(X1TD) and 5’-AGGGGATCCTGAAGGAGTTTGTGCAGTTT-3’ and 5’-TCGTCTAG 
ATCAGAGGAACCAGGACTGAG-3’ (X3TD).  To generate plasmids expressing NFI-
X1-FLAG and NFI-X3-FLAG the following reverse primers were used: 5’-TACCAGAT 
CTGAAAGTTGCCGTCCCGGGGTC-3’ and 5’-TACCAGATCTGAGGACCAGGAC 
TGAGAC-3’ 
 
 35 
2.3.8 Bisulfite sequencing. 250 ng genomic DNA were converted using EZ DNA 
methylation kit (Zymo Research, Orange, CA) according to the supplier’s instructions.  
Subsequently, PCR products were amplified using a pair of primers: 5’-
TGTAAGTAGATTTGGTAGT ATTGGGTTGG-3’ and 5’-
CCCTTTCCTAAACACAAACTAAATAAAACC-3’. PCR products were cloned into 
pCR2.1 (Invitrogen, Carlsbad, CA) and five clones were sequenced for each PCR 
product. 
 
2.3.9 Plasmids.  Reporter plasmids p10x(NFI)CAT and pGFAP(-1745)CAT were 
described previously [130]. The p21(-2400)Luc reporter was provided by Dr. Bert 
Vogelstein (Baltimore, MD) [131]. The p5xGAL4-Luc reporter and pCGal4 plasmid 
(pCDNA3.1 containing Gal4 DNA-binding domain) were gifts of Dr. Joseph Fontes 
(Kansas City, KS) [132, 133]. The PCR products containing full-length NFI-X1 and NFI-
X3 were digested with HindIII and XhoI, and cloned into the HindIII/XhoI sites of 
pcDNA5TO (Invitrogen, Inc. Carslbad, CA). To generate vectors expressing full-length 
NFI-X1-FLAG and NFI-X3–FLAG, the PCR products were digested with HindIII and 
BglII, and cloned into the HindIII/BamHI sites of pCMV5aFLAG (Sigma, St. Louis, 
MO). Subsequently, HindIII/XhoI fragments were cloned into the HindIII/XhoI sites of 
pcDNA5TO (Invitrogen, Inc. Carlbad, CA). The PCR products containing transactivation 
domains of NFI-X1 and NFI-X3 were digested with BamHI and XbaI, and cloned into 
the BamHI/XbaI sites of pCGal4.  
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2.3.10 Transfections.  Cells were transiently transfected in 12 well clusters using 
FuGENE6 transfection reagent (Roche, Indianapolis, IN), according to the supplier’s 
instructions.  One day after transfection the cells were harvested, protein extracts were 
prepared, and the protein concentration was determined by the BCA method (Sigma 
Chemical Co., St. Louis, MO).  Chloramphenicol acetyltransferase (CAT) and  β-
galactosidase assays were performed as described [134].  Luciferase (Luc) assays were 
performed using a Luciferase Reporter Assay Kit (Promega Corporation, Madison, WI). 
CAT and Luc activities were normalized to β-galactosidase activity and are means ± 
S.E.M. (5-7 determinations). To generate stable clones, 4 µg NFI-X1, NFI-X1-FLAG, 
NFI-X3, or NFI-X3-FLAG expression plasmids were transfected into a 10 cm dish of 
U373 cells. Clones selected in DMEM containing 75 µg/ml hygromycin were 
subsequently pooled. Nucleofection was used to transiently transfect U373 cells. Briefly, 
the cells (0.5x10
6
/well of 6-well dish) were trypsinized, collected by centrifugation and 
resuspended in 50 µl of T nucleofactor solution
TM
 (Amaxa, Inc, Gaithersburg, MD). The 
respective plasmids (0.8 µg) were added to the solution, and transfection was performed 
using a Nucleofector device (Amaxa, Inc, Gaithersburg, MD) with the electrical setting 
of T-20.  One ml of warm DMEM medium was added, and cells were incubated at 37°C 
for 10 min, and transferred to 6-well plates containing culture medium.  Typical 
nucleofection efficiencies were greater than 70% with cell viability close to 90%.  
 
2.3.11 Chromatin immunoprecipitation (ChIP) assay. Cells were crosslinked with 1% 
formaldehyde for 10 minutes at 37°C and then washed with ice-cold PBS containing 125 
mM glycine and 1 mM PMSF.  Chromatin was sonicated and immunoprecipitated using 
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specific antibodies exactly as described in the chromatin immunoprecipitation protocol 
from Upstate Inc. (Charlottesville, VA).  The following antibodies were used: anti-acetyl-
H3 (06-599, Millipore, Billerica, MA), anti-trimethyl-K4H3 (07-473, Upstate), anti-Pol II 
(05-623, Millipore), and anti-FLAG (M2) (Sigma, St. Louis, MO). The following primers 
were used in the qPCR: 5’-GCATCGCCAGTCTAGCCC-3’ and 5’-ATTCGAGCCAGG 
GAGAGGC-3’ for the GFAP promoter and 5’-TGCAAGCAGACCTGGCAGC-3’ and 
5’-GCAAGCCCCCTGCTCAATG-3’ for the GFAP enhancer. 
 
2.3.12 Mase protection assay.  Three 10 cm dishes of cells were used for nucleosome 
mapping. Briefly, cells were trypsinized, washed with cold PBS, and resuspended in 2 ml 
60 mM KCl, 15 mM NaCl, 5 mM CaCl2, 10 mM Tris pH 7.4, 300 mM sucrose, 0.1 mM 
EDTA, and 0.1% NP-40. Cells were lysed with a dounce homogenizer, nuclei were 
pelleted by centrifugation, and subsequently washed with 2 ml MNase digestion buffer 
(10 mM Tris pH 7.4, 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 
and 1 mM CaCl2). Nuclei were resuspended in 150 µl MNase digestion buffer (with 3 
mM CaCl2), 10 u of MNase was added, and samples were incubated for 1 h at 37ºC. 
DNA was purified using Puregene DNA purification kit (Qiagen, Valencia, CA). DNA 
was analyzed by gel electrophoresis (>95% typically represented mononucleosomal 
DNA), and subsequently quantified by qPCR using the Power SYBRGreen PCR kit 
(Applied Biosystems, Foster City, CA) and the following primers: (F1) 5’-CAGTGGGG 
TGAGGGGAG-3’; (F2) 5’-GCCTCTGGGCACAGTGAC-3’; (F3) 5’-GGCGTGCCCA 
GGAAGCTC-3’; (F4) 5’-CACCTGCCTCATGCAGGAG-3’; (F5) 5’-ATGGTCCAACC 
 38 
AACCCTTTC-3’; (R1) 5’-GCGAGGGCTTTATGAAGG-3’; (R2) 5’-TGGGCTAGACT 
GGCGATG-3’; and (R5) 5’-GAGGCAGGTGGTACCTGG-3’.   
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2.4 RESULTS 
2.4.1 FI-X3 splice variant expressed in astrocytes and glioma cells is highly 
conserved in mammals.  The structure of the fix gene is highly conserved in 
vertebrates, including Xenopus, rodents, canines, and primates. Moreover, the NFI-X 
mRNA is alternatively spliced in these species producing several splice variants that have 
been either cloned, or are predicted by the in silico analysis (reviewed in [128]).  In 
vertebrates, one of the splice variants (which we named NFI-X3 due to the homology of 
its C-terminal part to the previously cloned Xenopus’s NFI-X3) is generated by the 
inclusion of exon 9, which is absent in other splice variants, including NFI-X1 (Fig. 
2.2A).  The incorporation of exon 9 in the NFI-X3 mRNA generates a frame-shift placing 
the alternative exon 11’s STOP codon in frame.  As a result, the translated NFI-X3 
protein possesses a long proline-rich C-terminal transcription activation (TA) domain, 
which is unique to this splice variant (Fig. 2.1 and 2.2A).  On the amino acid level, the 
TA domain of NFI-X3 is 100% conserved in primates and dogs, while differs by only 
three and four amino acids in mice and rat, respectively (Fig. 2.1).  In contrast, the NFI-
X3 TA domain of Xenopus differs by 36 amino acids, including a three amino acid-long 
insertion (Fig. 2.1).  The functional properties of Xenopus’s NFI-X3 are not substantially 
different from the NFI-X1 and NFI-X2 splice variants [116].  However, the absolute 
conservation of the TA domain of NFI-X3 in primates (and dog) and over 95% identity in 
rodents, suggested that it may have acquired novel functions during the evolution of 
mammals.  Since the fix gene is important for mouse brain development and regulates 
gene expression in human astrocytes, we analyzed whether NFI-X3 is expressed by these 
cells.  In fact, NFI-X3 was expressed by primary human astrocytes, and at much lower 
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levels (5-10%) by glioma cell lines, which represent cells that escaped the astrocyte 
differentiation process (Fig. 2.2B and C).  Interestingly, glioma cells expressed low levels 
of all NFI-X transcripts, with the ratio of NFI-X3 to total NFI-X significantly reduced (by 
approximately 60% compared to astrocytes), thus suggesting that NFI-X3 may regulate 
gene expression during the differentiation towards astrocytes.  In order to analyze the 
functions of NFI-X splice variants, we amplified NFI-X3 and NFI-X1 from primary 
human astrocytes.  The C-terminal TA domains of astrocyte-derived NFI-X1 and NFI-X3 
were identical to the software-predicted domains.  However, in contrast to Xenopus NFI-
X3 and human NFI-X1, the N-terminus of human astrocyte-derived NFI-X3 is encoded 
by the alternative exon 1a (Fig. 2.2A). Thus, the unique conserved NFI-X3 splice variant 
is expressed by astrocytes, and it may be important for the differentiation of these cells. 
 
2.4.2 The TA domain of FI-X3 is critical for the regulation of gene expression in 
human astrocytes and glioma cells.  In order to analyze the transactivation potential of 
NFI-X3, we used several reporters that respond to NFI proteins [111, 130, 135]. These 
reporters were analyzed in transient transfection experiments of primary human 
astrocytes, glioblastoma, and HEK293 cells (Fig. 2.3). In addition to NFI-X3, we also 
used NFI-X1 to compare the transactivation by these two NFI-X splice variants. 
Significantly, NFI-X3, but not NFI-X1 activated the GFAP reporter in both astrocytes 
and glioblastoma cells  
 
 
 
 41 
Figure 2.1 Alignment of the amino acid sequences of the TA domains of FI-X3.  
Sequences were aligned with the ClustalW program. Dashes represent gaps introduced to 
maximize the similarity, grey box indicate identical sequences, while black boxes 
indicate sequences that are similar. The full length sequence of human NFI-X3 was 
deposited into GenBank (FJ861276). The following sequences were aligned: Macaca 
fasicularis (AB172261), Macaca mulatta (XM_001110545), Canis familiaris 
(XM_542036), Xenopus laevis [136], Homo sapiens (AAD38241), Mus musculus 
(NM_001081981), and Rattus norvegicus (EDL92203). 
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Figure 2.2 FI-X3 is expressed by astrocytes and glioma cells.  (A) A model of exon 
composition of the nfix gene, NFI-X1 and NFI-X3 transcripts (top panel), and the amino 
acid sequences of the predicted TA domains (bottom panel). (B, C) RNA was isolated 
from primary human astrocytes and the indicated glioma cell lines, reversed transcribed, 
and the expression levels of NFI-X3 (left panel) and total NFI-X (right panel) were 
analyzed by qPCR as described in the materials and methods. Data were normalized to 
GAPDH mRNA, and are presented as a percentage to human astrocytes set as 100%. 
NFI-X3 and NFI-X PCR products (after 31 cycles) were also analyzed by agarose gel 
electrophoresis (insert shown in B), using the indicated primers (XF and X3R for NFI-
X3, X1F and X1R for the total NFI-X). 
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(Fig. 2.3A); however, this reporter was not functional in HEK293 cells (data not shown).  
Since expression levels of both NFI-X3 and NFI-X1 were comparable (Fig. 2.3A, insert), 
we conclude that NFI-X3 may be critical for the transcription of GFAP in glial cells. In 
fact, the artificial NFI reporter, containing ten NFI binding sites linked to the minimal tk 
promoter [130], was similarly activated by 10-fold lower amounts of NFI-X3 than NFI-
X1 in human astrocytes (Fig. 2.3B).  In addition to the activator functions, NFIs also 
repress the expression of several genes, including p21(WAF1/CIP1) [135]. Surprisingly, 
both NFI-X3 and NFI-X1 efficiently repressed the expression of the p21 reporter in 
astrocytes, as well as HEK293 cells (Fig. 2.3C). These data suggest that the activation by 
NFI-X3 in glial cells may depend on its unique TA domain; however, the repression is 
likely mediated by a different part of the molecule, since the TA domains of NFI-X1 and 
NFI-X3 are very different (Fig. 2.2A).  To test these TA domains, we fused them to the 
Gal4 DNA binding domain (Fig. 2.4A), and co-transfected these constructs into 
astrocytes and HEK293 cells with the reporter plasmid p5xGAL4-luc, which contains 
five Gal4 binding sites linked to the Firefly luciferase gene [133]. The fusion protein 
containing the TA domain of NFI-X1 could not induce the Gal4 reporter either in 
astrocytes or HEK293 cells (Fig. 4B). In contrast, the fusion protein containing the TA 
domain of NFI-X3 activated the Gal4 reporter in both cell types (2.5 and 125 fold) (Fig. 
2.4B). Thus, the TA domain of NFI-X3 substantially differs in function from the one 
present in NFI-X1, and may regulate the expression of target genes in astrocytes. 
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Figure 2.3 Differential effects of FI-X3 and FI-X1 on various gene reporters.  
Primary human astrocytes and HEK293 cells were transiently transfected, while U373 
were nucleofected as described in the materials and methods. Cells were transfected or 
nucleofected with 100 ng of the indicated reporter plasmids, 400 ng NFI-X1 or NFI-X3 
expression vectors (A), or the indicated amounts of the expression vectors (B, C), as well 
as 50 ng β-galactosidase expression vector.  One day after transfection, cells were 
harvested. CAT or LUC activities were normalized to β-galactosidase activities to 
account for transfection efficiency. The putative binding sites for NFI, AP-1, p53, and 
SP1 are depicted on the cartoons representing the reporters. tk indicates a thymidine 
kinase minimal promoter. Inserts show the expression levels of NFI-X1 and NFI-X3. 
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Figure 2.4 Comparison of the activities of TA domains of FI-X1 and FI-X3.  
Primary human astrocytes were transiently transfected with 100 ng p5xGAL4-Luc, 400 
ng of the indicated expression plasmids, and 50 ng β-galactosidase expression vector.  
One day after transfection, cells were harvested. LUC activities were normalized to β-
galactosidase activities to account for transfection efficiency. Insert shows the expression 
levels of fusion proteins. Experiments were performed three times in duplicates. 
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2.4.3 Regulation of FI-X3 expression during astrocyte differentiation. We have 
recently developed an in vitro astrocyte differentiation model that allows the analysis of 
mechanisms regulating astrocyte-specific gene expression [121]. We used BG01V 
embryonic stem cells (ESC), differentiated them into neural progenitors (NP), and 
thereafter to astrocytes (Fig. 2.5). ESC and NP expressed only minute amounts of NFI-X 
(all NFI-X transcripts), including NFI-X3 (Fig. 2.5, top right panel). However, 
differentiation of NP to astrocytes resulted in the significant activation of NFI-X 
expression (~20 fold after 21 days), with even greater expression of the NFI-X3 (~37 fold 
in 21 days).  The expression of NFI-X3 preceded the expression of two markers of late 
astrocyte differentiation, GFAP and SPARCL1 (Fig. 2.5, bottom panels), therefore 
suggesting that NFI-X3 may regulate gene expression during the final stages of astrocyte 
differentiation. 
 
2.4.4 FI-X3 specifically regulates the expression of GFAP and SPARCL1 in human 
astrocytes and glioma cells. In order to evaluate whether NFI-X3 regulates the 
expression of GFAP and SPARCL1, we designed siRNA specifically targeting exon 9 of 
the nfix gene (Fig. 2.6A). For comparison, NFI-X SMARTPool siRNA was used to 
knock-down the expression of all NFI-X splice variants. In primary human astrocytes, the 
siRNA targeting exon 9 of the nfix gene efficiently and specifically knocked-down the 
expression of NFI-X3 (by 95%); however, this siRNA only diminished the expression of 
total NFI-X by 10% (Fig. 2.6A), and had no effect on the expression of NFI-A, -B, and -
C (data not shown). These results indicate that mRNA encoding NFI-X3 constitutes at the  
 
 51 
Figure 2.5 FI-X3, GFAP, and SPARCL1 are coexpressed during the 
differentiation of astrocytes. Embryonic stem cells (ESC) were differentiated into 
neural progenitors (NP), and then into astrocytes for 24 days as described in the materials 
and methods. RNA was isolated during this process every 3 days, reverse-transcribed, 
and the expression of NFI-X3, NFI-X, GFAP, and SPARCL1 was analyzed by qPCR. 
Target gene expression was normalized to GAPDH levels, and is represented as a fold 
induction in reference to NP cells. Experiments were performed three times in triplicates. 
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Figure 2.6 FI-X3 regulates the expression of GFAP and SPARCL1 in primary 
human astrocytes. Human astrocytes were transfected with 10 nM non-targeting siRNA 
(si-con), 10 nM siRNA targeting NFI-X3 (si-NFI-X3), or 10 nM siRNA targeting all 
NFI-X transcripts (si-panNFI-X). RNA was isolated after 48 hours and the expression of 
NFI-X3 and total NFI-X (A) and GFAP and SPARCL1 (B) were analyzed in triplicates. 
Data were normalized to GAPDH mRNA, and are presented as a fold induction in 
reference to untreated differentiated astrocytes.  
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most approximately 10% of the total pool of the NFI-X mRNAs in astrocytes. More 
importantly, the NFI-X3 knock-down resulted in the inhibition of GFAP and SPARCL1 
expression by 40% and 50%, respectively, which is almost identical to the repression 
found using siRNA targeting total pool of the NFI-X (Fig. 2.6B).  
Next we analyzed whether stable overexpression of NFI-X3 and NFI-X1 can induce 
the expression of GFAP and SPARCL1 in glioma cells. We have chosen U373 cells, 
which express relatively low levels of both of these markers, and generated pools of cells 
overexpressing NFI-X3 and NFI-X1 (Fig. 2.7A). Both of these cell pools upregulated the 
expression of GFAP and SPARCL1; however, overexpression of NFI-X3 resulted in 
massive induction of both markers, while overexpression of NFI-X1 had only a moderate 
effect (Fig. 2.7A and B). The data of the knock-down and overexpression experiments 
suggest that NFI-X3, although accounting at the most for only 10% of total NFI-X but 
possessing much greater transactivation potential than NFI-X1, regulates the expression 
of GFAP and SPARCL1 in both human astrocytes and glioma cells. 
 
2.4.5 Alterations in the architecture of the +1 nucleosome at the GFAP promoter are 
induced by the unique TA domain of FI-X3.  Recently, NFI-A has been shown to 
induce dissociation of DNA methyltransferase 1 from the gfap regulatory region and 
demethylation of the STAT3 binding site that is critical for the induction of GFAP 
expression [25].  To examine whether NFI-X3 activates GFAP expression via a similar 
mechanism, we analyzed methylation of CpGs at the gfap gene in the pools of cells 
expressing either vector, NFI-X3 or NFI-X1 (Fig. 2.8A).  However, all of the analyzed 
CpG, including the one located within the STAT3 binding element, were unmethylated in 
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Figure 2.7 Overexpression of FI-X3 but not FI-X3∆ dramatically induces the 
expression of GFAP and SPARCL1 in glioma cells.  Pools of U373 stable clones 
transfected with plasmids expressing either NFI-X1, NFI-X3, NFI-X3∆, or empty vector 
were cultured as described in materials and methods. RNA and cell lysates were prepared 
from the duplicate cultures, and media were collected. (A) The expression of NFIs, 
GFAP (cell lysates), and SPARCL1 (medium) was analyzed by western blotting. (B) 
RNA was reverse transcribed, and the expression of GFAP and SPARCL1 was analyzed 
by qPCR. 
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Figure 2.8 FI-X3 induces the recruitment of RA PolII to the gfap promoter.  (A) 
DNA was isolated from U373-Vec, U373-NFI-X1 and U373-NFI-X3 cells, bisulfite 
converted, and methylation of suitable CpG was analyzed as described in the materials 
and methods. Empty circles indicate demethylated CpGs.  (B) Lysates from U373-Vec, 
U373-NFI-X1-FLAG and U373-NFI-X3-FLAG cells were immunoprecipitated with anti-
FLAG antibodies, and precipitates were analyzed by western blotting using anti-CBP and 
anti-NFI antibodies (insert).  ChIP was performed using chromatin prepared from U373-
Vec, U373-NFI-X1 and U373-NFI-X3 cells, or U373-Vec, U373-NFI-X1-FLAG and 
U373-NFI-X3-FLAG cells as indicated. Both the gfap enhancer and core promoter were 
analyzed for the presence of acetylated-histone H3, trimethylated-K4H3, RNA PolII, and 
NFI-X1 or NFI-X3 (anti-FLAG) using the antibodies described in the materials and 
methods.  NRS indicates normal rabbit serum used for immunoprecipitation. Results are 
shown as a percentage of input. Experiments were performed three times. 
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of histone acetyltransferases by the STAT3/SMAD1 complex followed by acetylation of 
histones at the promoters of astrocyte-specific genes is another mechanism of their 
activation [114].  However, despite drastically different activation of the gfap gene by 
NFI-X3 and NFI-X1 (Fig. 2.7), both of this splice isoforms similarly interacted with CBP 
(Fig. 2.8B insert). Furthermore, histone acetylation at the gfap enhancer as well as core 
promoter was comparable in vector, NFI-X3, and NFI-X1 clone pools as determined by 
ChIP analysis (Fig. 2.8B) excluding histone acetylation as a mechanism of activation.  
Nevertheless, the recruitment of RNA PolII to the gfap promoter was significantly 
increased in NFI-X3 expressing cells, which also correlated with the increased histone 
H3 Lys4 trimethylation indicating ongoing transcription (Fig. 2.8B).  The increased 
recruitment of RNA PolII could be a result of stronger binding of NFI-X3 than NFI-X1 to 
the NFI binding elements.  To examine the binding of both of these splice variants at the 
gfap regulatory regions, we generated U373 pools expressing FLAG-tagged NFI-X1 and 
NFI-X3.  As expected, GFAP and SPARCL1 expression was strongly activated in NFI-
X3-FLAG expressing cells (Supplementary data Fig. 2.1).  Nevertheless, binding of both 
NFI-X1-FLAG and NFI-X3-FLAG to the gfap enhancer was similar (Fig. 2.8B), while 
they did not bind to the gfap promoter as previously reported [130].   
Nucleosomes are an impediment to transcription and therefore they are evicted or 
remodeled during gene activation [137, 138].  To understand the mechanism of NFI-X3-
induced activation of GFAP expression, we analyzed nucleosome positioning and 
occupancy at the gfap promoter using MNase protection assay combined with qPCR 
[139].  The +1 nucleosome was positioned at approximately -130 to +20 relative to the 
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gfap transcription start site in vector, NFI-X3, NFI-X3∆, and NFI-X1 clone pools (Fig. 
2.9A, and data not shown).  The upstream -1 nucleosome was also positioned at 
approximately -300 to -150 in the three cell types, indicating that both -1 and +1 
nucleosomes are not repositioned in cells overexpressing vector, NFI-X1, NFI-X3 or 
NFI-X3∆.  Subsequently, we analyzed the relative occupancy of the -1 and +1 
nucleosomes in all four cell types.  Although the accessibility of DNA to MNase 
cleavage at the -1 and +1 nucleosome was increased in NFI-X1 and NFI-X3 
overexpressing cells, the accessibility was significantly greater in NFI-X3 overexpressing 
cells (Fig. 2.9B).  More importantly, the accessibility of DNA to MNase cleavage of 
vector and NFI-X3∆ overexpressing cells was similar (Fig. 2.9B).  Since NFI-X1 and 
NFI-X3 differ by their TA domains, we conclude that the unique TA domain of NFI-X3 
induces stronger local changes in the promoter nucleosome architecture that allow for the 
increased RNA PolII recruitment and subsequent activation of GFAP expression. 
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Figure 2.9 FI-X3 induces alterations in the nucleosome architecture at the gfap 
promoter.  Nuclei were isolated from U373-Vec, U373-NFI-X1, U373-NFI-X3, and 
U373-NFI-X3∆ cells and digested with MNase as described in the materials and 
methods. (A) The positions of mapped -1 and +1 nucleosomes are indicated, and 
locations of qPCR primers are shown.  qPCR reactions were performed on MNase-
treated and total genomic DNA of U373-Vec cells, and the differences in Ct values are 
shown relative to the F5R5 qPCR product (Ct values for F5R5 were identical for genomic 
and MNase-treated DNA).  (B)  qPCR reactions were performed on both MNase-treated 
DNA of U373-Vec (vec), U373-NFI-X1 (X1) , U373-NFI-X3 (X3), and U373-NFI-X3∆ 
(∆) cells as indicated, and the differences in Ct values are shown relative to the -3kb 
qPCR product.  (C)  Model of transcriptional activation of the gfap gene expression by 
NFI-X3.  DNA is demethylated at the gfap enhancer, which allows for binding of the AP-
1, NFI-X1/NFI-X3, and STAT3 in U373-NFI-X1/NFI-X3 cells. At the gfap promoter 
histones are similarly acetylated in U373-NFI-X1 and U373-NFI-X3 cells. However, the 
unique TA domain of NFI-X3 induces stronger alteration of the nucleosome architecture 
(either remodeling or eviction) that allows for both the increased PolII occupancy and 
transcription of the gfap gene. 
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Supplemental Figure 2.1 Overexpression of FI-X3-FLAG dramatically induces the 
expression of GFAP and SPARCL1 in glioma cells.  Pools of U373 stable clones 
transfected with plasmids expressing either NFI-X1-FLAG, NFI-X3-FLAG, or empty 
vector were cultured as described in materials and methods. RNA was prepared from the 
duplicate cultures and was reverse transcribed, and the expression of GFAP and 
SPARCL1 was analyzed by qPCR. 
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2.5 DISCUSSIO 
It is apparent that NFIs are critical for the proper development of the brain, 
nevertheless the vital target genes regulated by NFIs and the molecular mechanisms of 
their regulation remain elusive. To date, multiple NFI-responsive genes have been 
identified in the brain, including the genes encoding GFAP, ACT, SPARCL1, S100B in 
astrocytes [28, 29, 121, 130], brain fatty acid binding protein in radial glial cells [35], 
myelin basic protein in oligodendrocytes [140], and mid-sized neurofilament in neurons 
[141].  Since regulatory sequences of these genes can bind all NFIs, their transcriptional 
regulation in a given cell type, in part, may depend on the availability of a particular NFI 
isoform, presence of the specific splice-variant, and likely the acquired post-
transcriptional modifications of the NFIs. In fact,  NFIs are expressed in complicated 
patterns during embryogenesis [27, 142], with NFI-A and NFI-B expressed during early 
gliogenesis [18], while NFI-X and NFI-C expressed later in the differentiation of 
astrocytes and control the expression of late astrocyte markers [121]. NFIs are also 
phosphorylated, and this modification affects their function [35].  
To date, the functional importance of the multiple NFI splice variants, as well as the 
mechanisms controlling their generation, remain largely unknown. Significantly, the NFI 
splice variants are evolutionary conserved in mammals, and their splicing mostly affects 
the C-termini encoding their TA domains: thus, suggesting that these variants likely 
fulfill very specific biological functions [128]. In particular, the inclusion of the exon 9 
found in the NFI-A, NFI-B, and NFI-C generates a subset of relatively active 
transcription factors (NFI-A1, NFI-B1, CTF-1). In contrast to these isoforms, the 
importance of alternative splicing of the NFI-X transcript was controversial, since 
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Xenopus and mouse splice variants containing exon 9 were reported not to be particularly 
active [116, 136]. However, the TA domain of Xenopus NFI-X3 is drastically different 
than the TA of the X3 variants found in mammals (Fig. 1). Moreover, the repressive 
properties of the previously cloned mouse NFI-X3 can be attributed to the partial TA 
domain that lacks 14 C-terminal amino acids [136].  In fact, the full length TA domain of 
the X3 splice variant is remarkably conserved in mammals, with 100% identity in 
primates and dog, and contains seventeen conserved proline residues (Fig. 2.1). These 
proline residues are likely responsible for the relatively strong activation of both the 
GFAP and NFI reporters by NFI-X3 in astrocytes and glioma cells (Fig. 2.3A and B), 
activation of GFAP and SPARCL1 expression in differentiating astrocytes (Fig. 5), and 
activation of GFAP and SPARCL1 expression in cells overexpressing NFI-X3 (Fig. 2.7). 
This is further supported by the findings that the Gal4 fusion protein containing the NFI-
X3 TA domain efficiently activated Gal4 reporter (Fig. 2.4), while siRNA specific to 
exon 9 (present in NFI-X3) abolished the activation of GFAP and SPARCL1 expression 
(Fig. 2.6). In contrast, NFI-X1 did not activate the GFAP reporter in astrocytes and 
glioma cells (Fig. 3A), mildly activated the NFI reporter in astrocytes (with 
approximately ten times lower efficiency than NFI-X3) (Fig. 3B), and only marginally 
activated SPARCL1 and GFAP expression when stably overexpressed in glioma cells 
(Fig. 2.7). Moreover, a fusion protein containing the NFI-X1 TA domain, and the Gal4 
DNA binding domain did not activate the Gal4 reporter (Fig. 2.4). These data suggest 
that NFI-X3 serves as strong transcriptional activator, while NFI-X1 is either a repressor 
or a very weak activator. Surprisingly, both NFI-X1 and NFI-X3 repress some genes 
independently of their TA domains, as observed for the p21 reporter (Fig. 2.3C) and p21 
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mRNA in cells overexpressing NFI-X1 and NFI-X3 (data not shown), nevertheless the 
mechanism of repression remains to be established.  
The question remains as to whether NFI-X3 plays an important biological role. Our 
data argue that NFI-X3 is solely responsible for the NFI-X-mediated regulation of GFAP 
and SPARCL1 expression in primary human astrocytes, since the down-regulation of 
NFI-X3 expression has an identical effect as the down-regulation of expression of the 
total NFI-X pool (Fig. 2.6). Although, NFI-X3 mRNA accounts at the most for only 
approximately 10% of the NFI-X mRNAs (Fig. 2.6A), the 10 times stronger activation 
potential (Fig. 2.3B) may explain its critical role in gene regulation.  Moreover, the 
expression of NFI-X3 is strongly upregulated during the differentiation of NP towards 
astrocytes, and precedes the activation of GFAP and SPARCL1 expression (Fig. 2.5). 
Importantly, the ratio of NFI-X3 mRNA/total NFI-X mRNA increases approximately two 
fold during the differentiation (Fig. 2.5). Conversely, this ratio is decreased in various 
glioma cells, already expressing low levels of all NFI-X transcripts (Fig. 2.2C), which 
may be viewed as cells that exited astrocyte differentiation. However, NFI-X3 expression 
is not restricted to glia, since we were also able to detect NFI-X3 mRNA in other non-
glial cells (data not shown); thus, indicating that NFI-X3 likely regulates transcription in 
various cell types.  
Although NFIs were discovered over two decades ago [143], the molecular 
mechanism of NFI-mediated gene activation still remains elusive.  Interestingly, NFIs not 
only bind to their specific binding elements within the regulatory regions of target genes 
but also interact with other transcription factors [144] and histone H3 [145].  Importantly, 
NFI-C (CTF-1) binding to histone H3, in part, depends on its TA domain [145].  NFI-C 
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can also be immunoprecipitated with remodeling complexes containing Brg1 [146], 
suggesting that chromatin remodeling may be the mechanism regulating NFI-dependent 
transcription.  Recently, the induction of the c-fos gene by MAP kinase signaling has 
been shown to depend on the acetylation relay switch that induces a local change in the 
nucleosome architecture allowing for NFI binding [147]. Nevertheless, how NFI 
recruitment increases c-fos expression is not clear.  Our data allow us to postulate a novel 
NFI-X3-specific model of gene activation that uniquely depends on the TA domain of 
NFI-X3.  Our data suggest that NFI-X3, but not NFI-X1, induces changes in the 
structure/occupancy of the +1 nucleosome positioned at the transcription start site of the 
gfap gene (Fig. 2.9B).  This localized alternation is likely an eviction of the +1 
nucleosome from the gfap promoter, which subsequently allows for the increased binding 
of the general transcription factors and the recruitment of PolII. However, due to the 
limitations of MNase accessibility assay, the NFI-X3-dependent remodeling of the +1 
nucleosome cannot be excluded. 
In summary, our data suggest that NFI-X3 is a critical splice variant of the nfix gene, 
which regulates expression of late markers such as GFAP in astrocytes via a splice 
variant-specific mechanism that depends on the induction of local alteration in chromatin 
architecture. 
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CHAPTER 3 
REGULATIO AD ROLE OF YKL-40 I GLIAL CELLS 
 
3.1 ABSTRACT 
Expression of a secreted glycoprotein YKL-40 is upregulated in various cancers, 
including highly invasive glioblastoma multiforme (GBM); however, functions of YKL-
40 and its regulation in the nervous system remained unexplored. Here, we report that 
YKL-40 expression is activated during mouse brain developmental and also during the 
differentiation of neural progenitors into astrocytes in vitro. In primary astrocytes, YKL-
40 expression is controlled by nuclear factor I-X (NFI-X) and signal transducer and 
activator of transcription 3 (STAT3), which are known to regulate gliogenesis. Indeed, 
knock-down of NFI-X and STAT3 significantly reduced YKL-40 expression in 
astrocytes, while overexpression of NFI-X3 (a splice isoform of NFI-X) dramatically 
induced YKL-40 expression in glioma cells. In addition, activation of STAT3 by 
oncostatin M induced YKL-40 expression in astrocytes, while overexpression of 
dominant-negative STAT3 had a suppressive effect. Interestingly, STAT3 activated 
YKL-40 expression via its binding site located in the YKL-40 proximal promoter, 
whereas direct NFI-X binding had not been detected. Surprisingly, NFI-X and STAT3 
physically interact and this complex likely regulates YKL-40 expression in astrocytes. 
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We further show that NFI-X controls migration and invasion of astrocytes and glioma 
cells, respectively, by regulating YKL-40 expression. These novel data suggest that 
YKL-40 is expressed by astrocytes during brain development and controls astrocyte 
migration.  
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3.2 ITRODUCTIO  
YKL-40, also known as chitinase 3-like-1 (Chi3L1), human cartilage glycoprotein 
39 (HcGP-39), and breast regression protein-39 (BRP-39), is a secreted glycoprotein 
expressed in both vertebrates and invertebrates [148, 149]. It belongs to the 18-
glycosylhydrolase family of proteins, but lacks glycolytic properties. It is secreted by a 
variety of cell types including macrophages, neutrophils, monocytes, chondrocytes, 
synovial cells, smooth muscle cells, endothelial cells, and several solid tumor cells 
including GBMs, osteosarcoma, and ovarian carcinoma [90, 91]. The biological functions 
of YKL-40 in normal physiological conditions remain poorly explored except that 
purified YKL-40 stimulates cell proliferation of several cell types including chondrocyte 
s, and synovial cells [91]. It is also known to be an adhesion and migratory factor for 
vascular smooth muscle cells, and endothelial cells [91]. Recently, an elegant study 
demonstrated that YKL-40 can work as an angiogenic factor [98].  
 Its expression is elevated in patients with a wide array of pathologies 
characterized by tissue destruction, ongoing inflammation, and development of fibrosis 
implicating its role in inflammatory processes and tissue remodeling. These pathologies 
include atherosclerosis, rheumatoid arthritis, osteoarthritis, giant cell arthritis, and 
sarcoidosis [91]. In agreement with its role in inflammation, YKL-40 knock out mice 
(BRP
-/-
) significantly lack antigen-induced Th2 responses [94]. Its expression is activated 
during the differentiation of macrophages and smooth muscle cell [92]. Several putative 
transcription factor binding sites including Sp-1, Stat, AP-1, CEBP, NF-kB and ETS have 
been predicted within the YKL-40 promoter region [92]. Among these, Sp-1 is 
responsible for YKL-40 expression during macrophage differentiation [92]. Several 
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cytokines including IL-1, TNF-α, and IL-6 can modulate its expression in many cell 
types including chondrocytes, macrophages, and GBMs [95] [93]. Increased levels of 
YKL-40 have been observed in a variety of  central nervous system (CNS) pathologies 
including Alzheimer’s disease (AD), and HIV associated dementia [103]. However, little 
is known about the source, regulation and role of YKL-40 in the CNS.  
Astrocytes constitute the majority of CNS cells and play critical roles in normal 
and pathology associated brain functions. Nevertheless, factors expressed, their 
regulation, and role during the astrocyte differentiation are only partially known. The 
astrocyte differentiation process is controlled by several signaling pathways, including 
the JAK-STAT pathway, BMP-SMAD pathway, and the Notch-HES pathway. Direct 
activation of JAK-STAT3 by IL-6 family cytokines, including, CT-1, LIF and OSM 
enhances astrocyte differentiation from neural precursor cells in vitro [17, 150].  In 
addition, a family of transcription factors called NFI (nuclear factor one) has also been 
shown to control astrocyte differentiation [18, 151]. NFI family consists of four members 
namely NFI-A, -B, -C, and –X. In mice, NFI family members are expressed in an 
overlapping pattern during embryogenesis, with high levels of NFI-A, -B, and -X 
expression in the developing neocortex [119]. In agreement to their expression, fia, fib 
and fix knock out mice show severe brain anatomical defects, including agenesis of 
corpus callosum [119, 142]. In addition, postnatal analysis of the fix null animals show 
defects in progenitor cell proliferation or migration [119]. Recently, NFI-A and –B has 
been shown to control gliogenesis in chick embryonic spinal cord, and we have recently 
shown that NFI-C and –X regulate the expression of late astrocyte marker genes during 
the astrocyte differentiation of human neural progenitors invitro [18, 151]. Furthermore, 
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to add to the complexity, NFI family members undergo alternative splicing to generate as 
much as 9 different variants from each gene. We have recently cloned and characterized a 
novel human splice isoform of NFI-X called NFI-X3, which is a potent activator due to 
its unique proline rich transactivation domain, regulating astrocyte marker gene 
expression (Singh SK Submitted). Although, JAK-STAT3 pathway and NFIs are critical 
regulators of astrocyte differentiation, the expression and function of their downstream 
target genes during astrocyte differentiation remain elusive.  
In this study, we show that YKL-40 is expressed and activated during the early 
period of postnatal mouse brain development, and also during astrocyte differentiation in 
vitro. Furthermore, its expression is regulated by NFI-X, and STAT3, the well known 
regulators of astrocyte differentiation. Functionally, YKL-40 works as a migration and 
invasion factor for astrocytes and glioma cells, respectively. We propose that YKL-40 is 
expressed during astrocyte differentiation and controls astrocyte migration to the proper 
location in the developing brain. This normal function of YKL-40 is utilized by glioma 
cells to migrate and invade surrounding tissue. 
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3.3 MATERIALS AD METHODS 
3.3.1 Cell culture. Human BG01V embryonic stem cells (ATCC, Rockville, MD) were 
cultured on mitomycin C-inactivated mouse embryonic fibroblast (MEF) layer. Cells 
were cultured in DMEM/F12 medium, supplemented with 20% knockout serum 
replacement (Gibco, Grand Island, NY), 1 mM L-glutamine, 0.1 mM nonessential amino 
acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 4 ng/ml basic fibroblast growth factor 
(bFGF) (PeproTech, Rocky Hill, NJ), and 0.1 mM β-mercaptoethanol. Cells were 
propagated in 4 day cycles, and enzymatically passaged with collagenase and trypsin. 
Human cortical astrocyte cultures were established using dissociated human cerebral 
tissue as previously described [129]. Cortical tissue was provided by Advanced 
Bioscience Resources (Alameda, CA), and the protocol for obtaining postmortem fetal 
neural tissue complied with the federal guidelines for fetal research and with the 
Uniformed Anatomical Gift Act. Human glioblastoma U373-MG cells were obtained 
from American Type Culture Collection (Rockville, MD) while human glioma LN229 
cells were obtained from Dr. Dimitry Kopitiniv (VCU, Richmond, VA).  Cells were 
cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf 
serum, antibiotics, sodium pyruvate, and non-essential amino acids. 
3.3.2 Generation of neural progenitors.  BG01V neural progenitors were generated 
exactly as described previously [121]. Briefly, cells were grown in DMEM/F12, 
supplemented with 15% defined FBS (Hyclone, Logan, UT), 5% KSR, 2 mM L-
glutamine, 0.1 mM nonessential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 
4 ng/ml bFGF, and 10 ng/ml leukemia inhibitory factor (LIF) (Chemicon, Temecula, 
CA). Subsequently, cells were grown for 7 days in differentiation medium composed of 
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DMEM/F12, N2 supplement (Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml 
penicillin, 50 µg/ml streptomycin, and 4 ng/ml bFGF. Subsequently, the MEF layer was 
removed and cells were dissociated by DPBS without calcium and magnesium, followed 
by collagenase and trypsin incubation. Cells were then plated on laminin and poly-L-
ornithin coated dishes, propagated in NB27 medium consisting of neurobasal medium, 
B27 supplement (both from Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml 
penicilin, 50 µg/ml streptomycin, 20 ng/ml bFGF, and 10 ng/ml LIF. Cells were 
maintained by passaging using trypsin.  
3.3.3 Differentiation into astrocytes. To generate astrocytes, neural progenitors were 
cultured on laminin and poly-L-ornithine coated dishes in DMEM, supplemented with 
10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, and 
nonessential amino acids for 21-24 days.  
3.3.4 Cytokines and Cell Stimulation. Cells were stimulated with 25 ng/ml OSM, or 25 
ng/ml IL-6 And sIL-6R (R&D, Systems, Inc., Minneapolis, MN. 
3.3.5 Down-regulation of target genes. Expression of NFI, NFI-X, STAT3, STAT1, 
YKL-40, c-Fos, Fra-1 and c-Jun mRNAs was down-regulated using SmartPool siRNAs 
(si-pan-NFI, si-panNFI-X, si-Stat3, si-Stat1, si-YKL-40, si-cFos, si-Fra-1 and si-cJun) 
from
 
Dharmacon (Dharmacon, Int., Lafayette, CO). The NFI-X3-specific siRNAs (si-
NFI-X3) was designed (Software provided on Dharmacon’s Website) to specifically 
target mRNA encoded by exon 9 (5’-UCCUAUG CCUGAUUCCAAAUU-3’).  siRNA 
was transfected into astrocytes, and U373-X3 cells using Dharmafect 1, according to the 
manufacturer’s instructions.  
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3.3.6 RA isolation and quantitative PCR. Total cellular RNA was prepared by Trizol 
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol. Subsequently, 1 µg of 
total RNA was reverse-transcribed using the High Capacity cDNA Archive kit (Applied 
Biosystems, Foster City, CA).  YKL-40, NFI-X, c-Fos and GAPDH mRNA levels were 
measured using pre-mixed primer-probe sets, and TaqMan Universal PCR Master Mix 
according to the supplier’s instructions (Applied Biosystems, Foster City, CA). The 
cDNAs were diluted 10-fold (for the target genes) or 100-fold (for GAPDH), and 
amplified using the ABI 7900HT cycler. Gene expression levels were normalized to 
GAPDH mRNA levels, and presented as a fold induction with mean values +/- standard 
deviation. Statistical analysis was performed by one-way analysis of variance. 
Differences were considered statistically significant when p-values were <0.05.  
3.3.7 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium 
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 
mM PMSF, and protease inhibitor cocktail (Roche, Mannheim, Germany).  Samples were 
resolved using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher 
& Schuell, Keene, NH). The anti-YKL-40, anti-NFI and anti-β-tubulin antibodies were 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and anti-Stat3 antibody from Cell 
Signaling Technology. Antigen-antibody complexes were visualized by enhanced 
chemiluminescence using Immobilon Western blotting kit (Millipore, Temecula, CA). 
3.3.8 Co-Immunoprecipitation. Protein lysates were prepared as described above. 
Briefly, lysates containing 200-300 µg protein were precleared with 25 µl of the protein 
G Sepharose 4 fast flow beads (GE Healthcare, Uppsala) for 1 hour. The precleared 
lysates were then incubated with 2 µg of anti-NFI antibody overnight at 40C. 
 78 
Subsequently, 30 µl of protein G sepharose beads were added and incubated for 1 h at 
40C. Beads were extensively washed with the lysis buffer and immunoprecipitated 
protein was eluted in sample buffer at 950C for 5 min. 
3.3.9 Synthetic oligonucleotides.  The following oligonucleotides were synthesized to 
mutate the STAT binding site in the YKL-40-Luc reporter (pStat-mutYKL-40 Luc) 5’-
ACATGCTAGCAAGCCCCCATCATCACCC-3’ and 5’-
GCTTGCTAGCATGTGACTCAGCCGCATTTCC-3’. The mutation in NFI binding site 
was generated by the following synthesized oligonucleotides 5’-
TCCACGAGCTCAAGGGGCCTGGAGTGAATGC-3’ and 5’-
CCCTGAGCTCGTGGAAACTGGGCTCAATTTAG-3. The following oligonucleotides 
were synthesized for the labeling, followed by EMSA experiments  5’-
GATCTCCACCTGGCCAGGGGCCTGGAGTGA-3’ and 5’-
GATCTCACTCCAGGCCCCTGGCCAGGTGGA-3’ (-467_NFI); and 5’-
GATCTTCAAGTTCCCATAAAAGGA-3’ (-155_STAT3). 
3.3.10 uclear extract preparation and EMSA. Nuclear extract from astrocytes and 
U373-X3-FLAG cells were prepared as described [151]. Double-stranded DNA 
fragments were labeled by filling in the 5′-protruding ends with Klenow enzyme using 
[α-
32
P]dCTP (3000 Ci/mmol). EMSA was carried out according to the published 
procedures [151]. Briefly, 5 µg of nuclear extracts and ∼10 fmol (10,000 cpm) of probe 
were used. The competition experiment was performed in the presence of a 100-fold 
excess of the cold oligonucleotides. anti-NFI (Santa Cruz Biotechnology, Santa Cruz, 
CA), anti-STAT3 (Cell Signaling Technology, Danvers, MA), and anti-Flag(M2) 
(Sigma-Aldrich, Saint Louise, MO) antisera were used for the supershift studies. 
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3.3.11 Plasmids.  The pYKL(-1300)Luc reporter was provided by Dr. Michael Rehli 
(University of Regensberg, Germany) (7). The STAT mutant plasmid pSTATmut1YKL-
40 Luc, pSTATmut2YKL-40 Luc and NFI mutant plasmid pNFImutYKL-40 Luc were 
generated using a Quick Change II site-directed mutagenesis kit (Stratagene, Cedar 
Creek, TX) and using the oligonucleotides described in the synthetic nucleotides section. 
The generation of plasmids expressing NFI-X1, and NFI-X3 are described elsewhere 
(Singh SK et. al submitted). 
3.3.12 Transfections.  Cells were transiently transfected in 12 well clusters using 
FuGENE6 transfection reagent (Roche, Indianapolis, IN), according to the supplier’s 
instructions.  One day after transfection the cells were harvested, protein extracts were 
prepared, and the protein concentration was determined by the BCA method (Sigma 
Chemical Co., St. Louis, MO).  Luciferase (Luc) assays were performed using a Dual 
Luciferase Reporter Assay Kit (Promega Corporation, Madison, WI). Luc activities were 
normalized to Renilla Luciferase activity (Promega Corporation, Madison, WI) and are 
means ± S.E.M. (5-7 determinations). Generation of stable cells overexpressing NFI-X1, 
NFI-X3 and NFI-X3-FLAG are described elsewhere (Singh SK et. al. submitted). 
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3.4 RESULTS 
 
3.4.1 Expression of YKL-40 is activated during both mouse brain development and 
astrocyte differentiation in vitro. YKL-40 is expressed during the development of 
various tissues including cartilage [91]. Since YKL-40 is expressed in glioblastomas, we 
analyzed its expression during mouse brain development. Indeed, YKL-40 expression 
gradually increases during the postnatal brain development at both RNA and protein 
levels (Fig. 3.1A, B), with YKL-40 mRNA levels increased approximately 7 fold at 
postnatal day 21 (P21) compared with P1.  
Since, astrocytes comprise the majority of the cells present within the brain and 
are generated during the late embryonic and early postnatal brain development [152], we 
explored whether these cells account for the YKL-40 expression. We have analyzed the 
expression of YKL-40 during the differentiation of human ESC towards NP and 
astrocytes in vitro [151]. Interestingly, YKL-40 is expressed at very low levels in ESCs 
and in NPs (Fig. 3.1C). However, the expression of YKL-40 is dramatically induced 
(approximately 60 fold) during the differentiation of NPs towards astrocytes (Fig. 3.1C). 
These data demonstrate that YKL-40 is expressed during astrocyte differentiation and 
also during mouse brain development. 
 
3.4.2 FI-X3 regulates the expression of YKL-40 in astrocytes and glioma cells. We 
have previously shown that NFI-C and NFI-X regulates the expression of terminal 
astrocyte markers, including GFAP and SPARCL1 in primary human astrocytes and 
human NP differentiating towards astrocytes [151]. We sought to explore whether NFIs 
also regulates YKL-40 expression. We specifically knocked-down the expression of 
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individual NFI members as well as the transcripts of all the NFI members together in 
astrocytes. In accordance, down regulation of NFI-X significantly reduced YKL-40 
expression (Fig. 3.2A). Furthermore, we have previously reported NFI-X3 a splice 
isoform of NFI-X predominantly controls astrocyte marker gene expression (Fig. 2.6, 
2.7). Indeed, we down-regulated NFI-X3 as well as the total pool of NFI-X in primary 
human astrocytes. Significantly, down-regulation of NFI-X as well as NFI-X3 resulted in 
the 50% and 30% reduction of YKL-40 expression, respectively (Fig. 3.2B). 
Next we analyzed the expression of YKL-40 in glioma cells (LN229) stably 
overexpressing either NFI-X1 or NFI-X3 splice isoform. NFI-X1 had a marginal effect 
on YKL-40 expression; however, NFI-X3 dramatically induced YKL-40 levels by 1500 
fold (Fig. 3.2C). To exclude the possibility of cell line specific effects, we stably 
overexpressed either NFI-X1 or NFI-X3 in U373 glioma cells and analyzed the 
expression of YKL-40. Similarly, NFI-X3, but not NFI-X1, strongly induced YKL-40 
expression (Fig. 3.2D and E) excluding the possibility of a cell line specific effect. These 
results strongly suggest that NFI-X3 regulates YKL-40 expression in astrocytes and 
glioma cells. 
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Figure 3.1 YKL-40 is expressed during early postnatal mouse brain development 
and human astrocyte differentiation invitro. YKL-40 expression in total brain 
homogenate was analyzed by western blotting (A) and qPCR (B) at the indicated times of 
mouse brain development. (C) Human embryonic stem cells (ESC) were differentiated 
into neural progenitors (NP) and subsequently to astrocytes. RNA was isolated every 3 
days (d), and the expression of YKL-40 was analyzed by qPCR. Target gene expression 
was normalized to GAPDH mRNA, and is represented as a fold induction in reference to 
NPs. 
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Figure 3.2 FI-X3 regulates YKL-40 expression in glioma cells and primary 
astrocytes. RNA was isolated from astrocytes transfected with indicated si-RNA for 48 
hours and the expression of YKL-40 was measured by q-PCR. Data is presented as the 
fold change of control si-RNA (Si-Con) cells (A). (B) Primary astrocytes were 
transfected with either scrambled si-RNA (si-Con), si-RNA targeting all the NFI-X 
isoforms (si-NFI-X) or si-RNA targeting specific splice isoform NFI-X3 (si-NFI-X3). 
48hr post transfection RNA was isolated and subsequently the expression of YKL-40 was 
measured and represented as % of control. RNA was isolated from stable pools of LN229 
(C) or U373 (D) cells transfected with empty vector, NFI-X1 or NFI-X3 expression 
plasmids, subsequently YKL-40 expression was measured by qPCR and normalized to 
GAPDH expression as described in materials and methods. (E) YKL-40 protein 
expression was detected in the conditioned media (CM) and the whole cell lysate (WCL) 
of U373 cells overexpressing either empty vector, NFI-X1 or NFI-X3 by western 
blotting. Tubulin was used as the loading control. 
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3.4.3 YKL-40 controls migration and invasion of astrocytes and glioma cells.  YKL-
40 has been shown to promote migration of vascular smooth muscle cells. Since high 
expression of YKL-40 is associated with invasive GBM tumors [97], we explored 
whether NFI-X3 controls migration and invasion of astrocytes and glioma cells via YKL-
40 dependent mechanism. The migration of primary astrocytes was reduced by 50% 
when NFI-X was downregulated (Fig. 3.3 left panel). Conversely, migration of astrocytes 
was markedly increased in response to exogenous YKL-40 (Fig. 3.3 right panel). 
Subsequently, we analyzed migration and invasion of glioma cells overexpressing NFI-
X3. Overexpression of NFI-X3 induced migration of U373 cells by approximately 2.5 
fold (Fig 3.4A left panel). Since YKL-40 expression was highly increased in U373-X3 
cells (Fig. 3.2D), we asked whether YKL-40 was responsible for NFI-X3 induced 
migration. Indeed, the down regulation of YKL-40 expression in U373-X3 cells 
drastically reduced  migration of these cells in wound healing assay (Fig. 3.4A right 
panel) and trans-well migration assays (Fig. 3.4B left panel).  Since YKL-40 is a secreted 
protein we further explored its role in enhanced migration of glioma cells. For this 
purpose, we collected the conditioned media of U373-X3 cells transfected with either 
control (Si-Con) or YKL-40 (Si-YKL-40) siRNAs, added these media to U373-vec cells, 
and analyzed the migration of these cells. Significantly, U373-vec cells migrated 2x more 
slowly in the presence of medium of Si- YKL-40 treated than Si-con-treated cells (Fig. 
3.4B right panel). These data indicate that NFI-X3 induced enhances glioma cell 
migration via the induction of secreted YKL-40 expression. 
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Figure 3.3 FI-X and YKL-40 control astrocyte migration. Astrocytes were 
transfected with si-RNA to scrambled (con si) or to NFI-X (si-NFI-X) fourty-eight hours 
post transfection, a scratch was made in the monolayer with a 2µl pipette tip. Cells were 
allowed to migrate for 15 hours. Pictures were taken at 0hr and 15 hours after the scratch 
was made (a). Astrocytes were plated to 95% confluency and grown overnight. 
Subsequently, scratch was made, and cells were allowed to migrate in the presence of 
media with or without purified YKL-40 (200ng/ml) for 15 hours. Pictures were taken as 
described above (b). Number of cells migrated in to the wound were counted from six 
random fields per experiments and represented as cells migrated per field. 
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Figure 3.4 FI-X3 and YKL-40 control glioma cell migration. Wound healing assay 
was done in U373 cells expressing vec or NFI-X3 (left); or in U373-X3 transfected with 
si-Con, or si-YKL-40, 30 hours post transfection scratch was made (right) and migrated 
cells in the wound area were counted at the indicated time points (A). (B) Transwell 
migration assay was done in U373-X3 cells with indicated si-RNA, number of cells 
migrated were counted on fibronectin coated membrane (left); or in U373-vec cells, 
migration was analyzed in the presence of CM from si-Con, or si-YKL-40 transfected 
U373-X3 cells (right). 
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Figure 3.5 FI-X3 and YKL-40 control glioma cell invasion. Matrigel invasion assay 
was done with U373-vec or U373-X3 on boyden chamber slide (left), or with U373-X3 
cells transfected with si-con or si-YKL-40 (right), cells were allowed for 8 hours to 
invade through the matrigel. Number of cells invaded in the matrigel were counted from 
six random fields per experiments and represented as cells invaded per field. 
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Since YKL-40 has been shown to increase the in vitro invasion of transformed 
astrocytes [153], we tested whether NFI-X3 and YKL-40 regulate glioma invasion. 
Indeed, cells overexpressing NFI-X3 were twice more invasive                                       
(Fig. 3.5 left panel), and siRNA to YKL-40 diminished their invasion by 40% (Fig. 3.5 
right panel). Taken together, these data strongly suggest that YKL-40 controls migration 
and invasion of astrocytes and glioma cells, respectively. 
 
3.4.4 The expression of YKL-40 is induced by the cytokines of IL-6 family. Since 
signaling through the JAK-STAT3 pathway is critical for astrocyte differentiation, and 
IL-6 family cytokines activate JAK-STAT3 signaling, we sought to explore whether 
YKL-40 is regulated by the JAK-STAT pathway. To this end, we stimulated astrocytes 
with OSM and also IL-6 together with soluble IL-6 receptor (sIL-6R) (since astrocytes 
express limited amount of IL-6R). Expression of YKL-40 mRNA was activated by 8-10 
fold by OSM and 3 fold by IL-6/sIL-6R (Fig. 3.6A). OSM-stimulated YKL-40 
expression was time-dependent (Fig. 3.6B) and was followed by the increased secretion 
of YKL-40 into the medium (Fig. 3.6C).  
 
3.4.5 STAT3 and FI-X are critical for OSM-stimulated YKL-40 expression. To 
identify which of the STATs control YKL-40 expression, we down-regulated the 
expression of STAT1 and STAT3 which are known to be activated by OSM. Down 
regulation of STAT3 alone or together with STAT1 reduced basal expression of YKL-40 
by approximately 50% and almost completely abolished the OSM stimulation of YKL-40  
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Figure 3.6 Effect of IL-6 family cytokine treatment on YKL-40 expression in Ps 
and Astrocytes.  Astrocytes were stimulated with the indicated IL-6 family members for 
24 hours. Then cells were trizol lysed and RNA was isolated subsequently YKL-40 
expression was analyzed by qPCR (A). Astrocytes were stimulated with OSM for 
indicated time points and YKL-40 expression was analyzed by qPCR (B). YKL-40 
expression was normalized with GAPDH, and represented as fold change compared to 
unstimulated cells. YKL-40 expression was detected by western blotting in CM and 
WCL of astrocytes stimulated with OSM for 24 hour. Tubulin was used as loading 
control (C). 
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expression (Fig. 3.7). In contrast, STAT1 knock-down had no effect (Fig. 3.7). These 
data suggest that STAT3, but not STAT1, controls OSM induced YKL-40 expression in 
astrocytes. 
Since NFI-X regulates basal expression of YKL-40 in astrocytes and glioma cells 
(Fig. 2), we asked if it is also critical for the OSM-induced expression. We down -
regulated the expression of NFI-X and also all NFIs (pan-NFI) and analyzed the 
expression of basal and OSM induced YKL-40 mRNA in astrocytes. Surprisingly, knock-
down of NFIs or NFI-X diminished the basal and almost completely abolished the OSM 
induced YKL-40 expression (Fig. 3.7), implying that NFI-X is a critical factor regulating 
the expression of YKL-40 in astrocytes. In another approach we utilized our glioma cells 
stably overexpressing NFI-X1 or NFI-X3 and measured YKL-40 expression upon OSM 
treatment. Indeed, the expression of YKL-40 was induced by approximately 4-6 fold in 
the cells overexpressing NFI-X1 or -X3, but not cells transfected with empty vector (Fig. 
3.8). Collectively, these data clearly demonstrate that both STAT3 and NFI-X are  
needed for OSM-induced YKL-40 expression in primary astrocytes. 
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Figure 3.7 STAT3 and FI-X are essential for OSM stimulated upregulation of 
YKL-40 in astrocytes. Astrocytes were transfected with indicated si-RNA. 40 hours post 
transfection cells were stimulated with OSM for 24 hours and subsequently YKL-40 
expression was analyzed by qPCR. YKL-40 expression is represented as fold change 
compared to unstimulated cells. 
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Figure 3.8 FI-X1 and FI-X3 isoform are critical for OSM stimulated YKL-40 
expression in glioma cells. U373 and LN229 cells stably overexpressing either empty 
vector, NFI-X1 or NFI-X3 were stimulated with OSM for 24 hours. Cells were lysed and 
RNA was isolated subsequently YKL-40 expression was analyzed by qPCR. Target 
expression was normalized with GAPDH and represented as fold induction compared to 
unstimulated empty vector expressing cells. 
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3.4.6 Identification of regulatory elements within the YKL-40 promoter critical for 
its activation by OSM. To further characterize the mechanism of YKL-40 regulation by 
STAT3 and NFI-X, the 1.3 kb upstream region of the human YKL-40 gene was screened 
for the putative regulatory elements using MAT-INSPECTOR and TRANSFAC 
programs (Fig. 3.9A) and one AP-1, two STAT, and four NFI binding elements were 
identified. We obtained the -1.3kb YKL-40 promoter cloned in front of the luciferase 
reporter gene (pYKL(-1300)-Luc) from Dr. Michael Rehli. 
To assess the importance of STAT binding elements, we made mutants of each 
STAT binding site in the pYKL(-1300)-Luc plasmid. Astrocytes were transfected with 
either pYKL(-1300)-Luc or p-STATmut1-YKL-Luc or p-STATmut2-YKL-Luc and 
stimulated with OSM. A moderate 3-fold induction in Luciferase reporter activity is 
observed (Fig. 3.9A) upon OSM stimulation in the wild type reporter plasmid, suggesting 
that OSM stimulated YKL-40 expression is due to the enhanced YKL-40 promoter 
activity. As evident from the data, mutation in STAT binding site 1 dramatically reduced 
the basal as well as OSM stimulated Luciferase reporter activity (Fig. 3.9A). However, 
mutation of the STAT site 2 has no effect on reporter activity. These data implicate that 
OSM stimulated YKL-40 reporter activity is mediated through STAT binding site 1 
present within the YKL-40 proximal promoter. 
 To further validate the importance of STAT3 factor in OSM stimulated YKL-40 
expression, we transfected primary astrocytes with pYKL(-1300)-Luc plasmid together 
with plasmids expressing empty vector, constitutive active STAT3 (CA-STAT3) or 
dominant negative STAT3 (DN-STAT3) and analyzed the Luciferase activity. 
Interestingly, CA-STAT3 further enhanced the OSM stimulated reporter activity and had 
 102 
no effect on basal YKL-40 reporter activity. Conversely, DN-STAT3 abolished the OSM 
stimulated YKL-40 reporter activity and basal YKL-40 Luciferase activity was 
unaffected (Fig. 3.9B). 
 Since OSM is known to transcriptionaly activate AP-1 family members [154] and 
there is a single AP-1 binding element within the YKL-40 promoter, we sought to 
explore the involvement of AP-1 element in OSM induced YKL-40 reporter activation. 
To test this we made a mutation in the AP-1 binding element within the YKL-40 reporter 
plasmid (p-mutAP-1-YKL-Luc), and transfected the mutant constructs into astrocytes. 
Surprisingly, mutation in AP-1 binding element significantly reduced the OSM induced 
YKL-40 reporter activity by 40%, and had no effect on basal reporter activity (Fig. 3.9A). 
Moreover, a double mutant of STAT and AP-1 element (p-mutSTAT-AP-1-YKL-luc) 
completely abolished the OSM induced YKL-40 reporter activity (Fig. 3.9A), suggesting 
both STAT and AP-1 elements are necessary for OSM induced YKL-40 reporter activity. 
 To evaluate the effect of putative NFI binding elements, we made a deletion 
mutant (p-delYKL-40-Luc) removing two of the putative NFI binding elements of YKL-
40 reporter, furthermore we utilized this deletion mutant plasmid to remove the 3
rd
 NFI 
binding element by mutagenesis (p-mut-NFI YKL-Luc). These plasmids were transfected 
into astrocytes and luciferase activity is measured after OSM stimulation. Interestingly, 
none of these mutant plasmids had any effect on either basal or OSM stimulated reporter 
activity (Fig. 3.9A) ruling out the involvement of the NFI binding elements in YKL-40 
promoter activation.  
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Figure 3.9 STAT3 and AP-1 but not FI elements are critical for OSM induced 
YKL-40 reporter activity in astrocytes. Astrocytes were transfected with indicated 
reporter plasmids as described in materials and methods and stimulated with OSM for 24 
hours (A). Indicated expression plasmids were co-transfected with pYKL(-1300)Luc, 8 
hours post transfection cells were stimulated with OSM for 24 hours (B).  Luciferase 
reading was measured and normalized by renilla reading. Data is represented as relative 
Luciferase activity as fold change compared to pYKL(-1300)Luc control plasmid. 
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Combining all these data we can conclude that STAT and AP-1 elements are 
critical for YKL-40 reporter activation upon OSM treatment and that NFI elements do 
not regulate YKL-40 promoter activation. 
 
3.4.7 DA-Protein interaction studies to the YKL-40 regulatory elements 
demonstrate the binding of STAT-3 and AP-1 family members:   From the reporter 
analysis it is clear that STAT and AP-1 elements are needed for OSM stimulated YKL-40 
promoter activation. Supershift assays showed STAT-3 as well as STAT-1 binding to the 
YKL-40 promoter (Fig. 3.10A). Since, mutation of NFI elements showed no effect on 
YKL-40 reporter activity and close analysis of YKL-40 promoter revealed a non-
consensus NFI element close to STAT element (Fig. 3.9A). Indeed, NFI and STAT 
proteins are capable of binding, rather with low efficiency, to the NFI-STAT element as 
demonstrated by competition with cold probe and antibody supershift assays (Fig. 
3.10B). AP-1 family of transcription factors consists of c-Fos, Fos-B, Fra-1, Fra-2, c-Jun, 
JunB, JunD etc.  The obvious question we asked which of these members are involved in 
the OSM regulated YKL-40 activation. The amount of DNA-protein complex is 
enhanced at the AP-1 element of the YKL-40 promoter upon OSM stimulation (Fig 
3.10C left panel). Moreover, supershift assays demonstrated the identity of AP-1 
members, c-Fos, Fra-1, c-Jun and JunB bound to the corresponding AP-1 element (Fig 
3.10C right panels). Interestingly, the binding of c-Fos was transient and could only be 
observed at one hour of stimulation  
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Figure 3.10 Binding of AP-1 complex to the putative binding element located at the 
5` flanking region of the YKL-40 gene. Nuclear extracts from control astrocytes or 
astrocytes stimulated with OSM for 4 hrs were analyzed by EMSA using oligonucleotide 
corresponding to an AP-1 site (A). Supershift was performed using antibodies against c-
Fos, Fos-B, Fra-1, Fra-2, c-Jun, Jun-B, Jun-D and non rabbit serum control nuclear 
extract (NRS) (B) and 4hr OSM stimulated nuclear extract (C). Ten and 100 fold excess 
of cold oligonucleotide competitors were added to the binding reaction as indicated. 
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Figure 3.11 OSM stimulated YKL-40 expression does not depend on c-Fos, Fra-1 
and c-Jun. Astrocytes were transfected with indicated si-RNA, and stimulated with OSM 
for 20 hr or unless as indicated time for 1hr, 4hr or 20 hr and RNA was isolated and 
subsequently  the expression of YKL-40 (A-, B-left panels and C), c-Fos ( A-middle and 
-right panels) and c-Jun (B right panel)  was analyzed by qPCR. Data are normalized by 
GAPDH expression and represented as fold change compared to unstimulated si-Con 
cells. 
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while other members were observed at both the stimulation time points one and four 
hours (Fig. 3.10C).  
  It is well documented that OSM can stimulate c-Fos, Fra-1, c-Jun and JunB 
expression in various cell types [155] [154]. In addition, NFI transcription factors are also 
essential for PMA stimulated c- Fos expression [147]. We knocked-down the expression 
of c-Fos, Fra-1, JunB and c-Jun using si-RNA in astrocytes and measured YKL-40 
expression after stimulation with OSM. Surprisingly, none of the si-RNA showed any 
effect on OSM induced YKL-40 expression, suggesting involvement of another member 
(Fig. 3.11). 
 
3.4.8 FI-X and STAT3 physically interact: Both NFI-X and STAT3 regulate YKL-40 
expression (Fig. 2 and 5) and STAT and NFIs bind to the NFI-STAT element within 
YKL-40 promoter (Fig. 3.10B). Therefore we sought to explore whether STAT3 may 
directly recruit NFI-X to the YKL-40 promoter via direct STAT/NFI-X interaction. We 
Immunoprecipitated NFI-X and found that STAT3 efficiently co-immunoprecipitated 
from NFI-X3 and NFI-X1 cell lysates (Fig. 3.12A). Significantly, NFI-X3 interacted 
more efficiently with STAT3 and OSM stimulation further increased this interaction (Fig. 
3.12A). In another approach, we have cotransfected NFI-X1Flag or NFI-X3Flag 
expressing constructs with STAT3-V5 palsmid and analyzed their interaction with 
STAT3 in HEK cells. Indeed, NFI isoforms interacted with STAT3-V5 tagged protein 
supporting our data from U373 cells. Interestingly, this interaction remained unaffected 
after OSM stimulation (Fig. 3.12B) suggesting a cell type specific interaction. 
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Figure 3.12 FI-X3 and STAT3 physically interact. (A) Co-immunoprecipitation was 
performed from U373-Vec, -X1 or –X3 lysates using NFI antibody. Immunoprecipitated 
samples were run on SDS-PAGE and STAT3 was detected in western blotting. Western 
blotting for STAT3 and NFI was also done from total lysates (bottom panel). (B) HEK 
cells were transfected with indicated plasmids. Post 24 hour transfection respective cells 
were stimulated with OSM for 15 minutes and total cell lysates was prepared. 
Subsequently, flag tagged protein was pull down by Flag beads followed by western blot 
(WB) using V5 and NFI antibodies to detect STAT3-V5 and NFI-Flag proteins.  
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Thus, NFI-X and STAT3 physically interact and STAT3 may recruit and stabilize NFI-X 
binding to the relatively poor NFI consensus site within the YKL-40 promoter. To our 
knowledge this is the first report that NFI-X and STAT3 factors physically interact and 
may control gene expression. 
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3.5 DISCUSSIO 
 YKL-40 is a shared biomarker of inflammation and oncogenic transformation (*). 
Accordingly, increased levels of YKL-40 can be detected in various CNS pathological 
states associated with ongoing inflammation, including AD [103], MS  and glioblastoma 
[153]; however, the cells which express YKL-40 remains controversial. In fact, a recent 
study demonstrated that YKL-40 is expressed by activated microglial cells in the SIVE 
associated inflammation [102]. Nevertheless, YKL-40 expression in GBM cells, which 
are of astrocytic origin, argues that YKL-40 may be expressed in astrocytes as well [153]. 
Here, we report that primary human astrocytes express and secrete YKL-40 (Fig. 2 A), 
YKL-40 is also expressed during the differentiation of neural progenitor cells towards 
astrocytes (Fig. 1 C), and YKL-40 expression is induced during postnatal mouse brain 
development (Fig. 1 A, B). Interestingly, expression of YKL-40 during the postnatal 
period P1 to P21 coincides with the differentiation and maturation of astrocytes in mouse 
brain in vivo (E16 to P30) (19), suggesting that astrocytes may contribute to the induced 
YKL-40 expression in the developing brain. Indeed, transcriptome analysis of the mouse 
neurons, astrocytes and oligodendrocytes revealed that YKL-40 is expressed in astrocytes 
from P1 to P30 [152]. 
 Astrocyte differentiation is executed by several signaling pathways including, 
JAK-STAT3, BMP-SMAD and Notch-Hes during embryonic mouse brain development 
[17, 18, 105]. In vivo, IL-6 family cytokines including CT-1, LIF, IL-6 and OSM has 
been shown to activate JAK-STAT3 pathway and subsequently induce astrocyte 
differentiation [156]. In addition, recently a family of transcription factors called NFI has 
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also been shown to control astrocyte differentiation. The family comprises of four 
members NFI-A,-B,-C, and -X. More specifically, NFI-A and –B control early phase of 
gliogenesis while, NFI-X and –C control marker gene expression during late phase of 
astrocyte differentiation [18] [157]. Here we report that YKL-40 expression in astrocytes 
is primarily regulated by NFI-X, to a lesser extent by NFI-C, but not by NFI-A or –B 
(Fig. 2 A). Importantly, NFI-X3 (a splice isoform of NFI-X) seems to regulate YKL-40 
expression since down-regulation of NFI-X3 in astrocytes and its overexpression in 
glioma cells significantly affect YKL-40 expression (Fig. 2 B, C, D and E). In addition, 
the expression of NFI-X3 precedes the expression of YKL-40 during astrocyte 
differentiation (Fig. 1C and data not shown). Moreover, it is of interest, whether the 
regulation of YKL-40 by NFI-X is astrocyte specific. Indeed, knock down of NFI-X and 
NFI-C had no significant effect on the expression of YKL-40 in THP-1 monocytes, 
suggesting cell type specific regulation (data not shown). 
 IL-6-type cytokines activate the expression of YKL-40 in astrocytes (Fig. 4) and 
this activation depends on NFI-X and STAT3 (Fig. 5). STAT-3 binds to the STAT 
binding element of YKL-40 promoter (Fig. 7C)) and this element is critical for OSM 
induced activation (Fig. 6A). Since YKL-40 is induced during astrocyte differentiation 
(Fig. 1C), it is not surprising that the NFI-X and STAT3, both important regulators of 
gliogenesis, control YKL-40 expression. OSM efficiently activates JAK-STAT3 pathway 
and receptor for OSM (OSMR) is expressed in neuroepithelial cells and differentiating 
astrocytes [150]. Therefore, it is speculative that OSM activates astrocyte differentiation 
and YKL-40 expression during embryonic brain development. 
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Although NFI-X regulates YKL-40 expression (Fig. 2 and 5), and there are three 
putative NFI binding elements within the -1.3 kb YKL-40 promoter, deletion and 
mutation to these NFI binding sites had no effect on the YKL-40 reporter activity (Fig. 
6A). These data rule out the possibility of direct binding of NFI-X to these regulatory 
elements. NFI-X may also bind to the elements located outside of the -1.3kb long 
promoter. However, our data suggests that NFI-X is indirectly recruited to the YKL-40 
promoter by STAT3 that binds to the proximal STAT element. This is strongly supported 
by the following observations: both NFI and STAT3 weakly bind to the oligonucleotide 
harboring both NFI and STAT elements in vitro (Fig. 7C); also STAT3 and NFI-X are 
found in a complex (Fig. 8A and B). Interestingly, the interaction of STAT3 with NFI-X3 
is stronger than NFI-X1, which lacks proline rich transcriptional activation (TA) domain 
(Fig. 8A). Since, proline rich domains are often involved in protein: protein interactions 
[158], it is possible that in part, NFI-X3 interacts with STAT3 via its TA domain. It 
remains to be explored whether a NFI-X/ STAT3 complex controls a specific subset of 
the astrocyte-specific genes during the differentiation. Significantly, a specific subset of 
genes regulated by the STAT3:NF-κB complexes have recently been shown to differ 
from genes regulated by STAT3 [159]. Since STAT3 is ubiquitously expressed and 
controls a wide variety of cell functions, it is proposed that its interactions with other 
transcription factors provide tissue specific functions [159]. 
 NFI-X3 controls astrocyte and glioma cell migration and invasion via regulating 
expression of YKL-40 (Fig. 3B, C, and D). In addition, exogenous YKL-40 controls 
astrocyte migration (Fig 3A right panel). These data support previous findings that 
transformed astrocytes overexpressing YKL-40 are more invasive [153].  Moreover, NFI-
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X knock-out mice show defects in migration of the subventricular zone progenitor cells 
[119]. Similar to NFI-X, NFI-A and –B control tangential neuronal migration by 
regulating the expression of ephrin-B1, and N-cadherin which are cell adhesion 
molecules [160]. Thus, different NFIs likely regulate different target genes to affect cell 
migration. 
In conclusion, we propose that NFI-X and STAT3 control the migration of 
differentiating astrocytes as well as migration and invasion of glioma cells via regulating 
YKL-40 expression. 
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CHAPTER: 4  
SUPPLEMETARY OBSERVATIOS 
 
4.1 ITRODUCTIO 
High serum level of YKL-40 is associated with wide variety of inflammatory 
conditions including encephalitis, meningitis, asthma, rheumatoid arthritis, and 
sarcoidosis. Noteworthy, YKL-40 is rarely observed in the serum of healthy individuals 
Therefore, it is regarded as one of the prominent markers of inflammatory conditions 
which is mainly expressed by differentiated macrophages, and neutrophils [91]. 
According to the predicted role of YKl-40 in inflammation, YKL-40 knock out mice 
show diminished antigen-induced Th2 responses partly due to the lack of IL-13-induced 
tissue inflammation, and alternative macrophage activation [94]. High levels of YKL-40 
were observed in several neurological disorders, including Alzheimer’s disease, 
Parkinson’s disease, Multiple sclerosis, and Schizophrenia [97, 103, 104]. These 
pathologies are associated with the ongoing CNS inflammation, suggesting that YKL-40 
may play some important but yet to be identified role in these CNS pathologies. 
Interestingly, microglia and astrocytes are the major modulators of inflammatory 
responses, which produce various cytokines, chemokines and neurotrophic factors. In 
fact, alternatively activated microglia were accounted for the elevated levels of YKL-40 
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in AD patients [103]. Nevertheless, astrocytes become reactive in response to 
inflammation or injury and also can be a source of YKL-40 (chapter 3).  
 
4.2 RESULTS 
4.2.1 Pro-inflammatory cytokines stimulate YKL-40 expression in astrocytes: The 
regulation of YKL-40 expression in reactive astrocytes has not been explored to date. 
Since astrocytes produce YKL-40, we tested whether a combination of 
neuroinflammatory cytokines, including IL-6, OSM, and IL-1 regulate YKL-40 
expression. Indeed, YKL-40 expression was activated by IL-1 or IL-6+sIL-6r and OSM 
(6-10 fold), but was synergistically enhanced by combination of IL-1 and OSM (200-300 
folds) and IL-1 and IL-6+sIL-6r (50 folds) (Fig. 4.1). 
 
4.2.2 Astrocytes but not microglia respond and secret YKL-40 in response to 
cytokines: In order to compare regulation of YKL-40 expression in microglia with its 
regulation in astrocytes, we stimulated rat primary microglial cells with IL-1, IL-6/sIL-
6R, and TNFα. We also used LPS (Lipo-polysaccharide) as the positive control for 
microglial activation. Moreover, none of these cytokines were able to enhance YKL-40 
expression or induce its secretion (Fig. 4.2 right panel). Since microglia do not express 
receptors for IL-1, TNF, IL-6 they were not able to respond. Surprisingly, LPS a strong 
activator of microglia also failed to activate YKL-40 expression and secretion in these 
cells. These data suggest that YKL-40 is regulated both at the level of its transcription 
and protein secretion in a cell specific manner. This is supported by the findings that 
astrocytes respond to cytokine stimulation and induce YKL-40 expression as well as 
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secretion (Fig 4.2 left panel). However, microglia are insensitive to cytokine stimulation 
in terms of YKL-40 expression and secretion. As a result of these observations we 
propose that activated astrocytes are primary source of YKL-40 in CNS pathologies. 
Figure 4.1 Effect of pro-inflammatory cytokine on the YKL-40 expression in 
Astrocytes.  Astrocytes were stimulated with the indicated cytokines for 24 hours. Then 
cells were trizol lysed and RNA was isolated. Subsequently YKL-40 expression was 
analyzed by qPCR. YKL-40 expression was normalized with GAPDH, and represented 
as fold change compared to unstimulated cells.  
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Figure 4.2. Comparison of YKL-40 expression between astrocytes and microglia.  
Primary human astrocytes and Primary rat microglia (derived from postnatal rat brain day 
3 P-3) were grown overnight in serum free media followed by stimulation with the 
indicated cytokines for 24 hours. Conditioned media was collected and cells were lysed 
in denaturing cell lysis buffer. Conditioned media was concentrated ten times and run on 
SDS-PAGE with the total cell lysates. Subsequently YKL-40 expression was analyzed by 
western blotting. Tubulin is used as loading control. 
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4.2.3 YKL-40 inhibits Myelin basic protein (MBP) expression during 
oligodendrocyte differentiation in vitro. Since YKL-40 is a secreted molecule, it may 
interact with and affect functions of other cell types in a paracrine manner. Indeed, a 
recent study has demonstrated that YKL-40 inhibits bFGF-induced dendrite formation in 
hippocampal neurons [102]. In preliminary experiments we found that YKL-40 inhibits 
myelin basic protein (MBP) gene expression during the differentiation of oligodendrocyte 
progenitor cells (OPCs) (Fig. 4.3).  
These data are of great interest considering that high levels of YKL-40 are found 
in MS [104]. Thus, YKL-40 could be one of the molecules produced by reactive 
astrocytes, which may contribute to the MS pathology. However, the exact role of YKL-
40 in oligodendrocyte differentiation and myelin production remains to be studied in the 
future. 
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Figure 4.3. Effect of purified YKL-40 on rat oligodendrocyte progenitor cell 
differentiation.  Oligodendrocyte progenitor cells (OPCs) were isolated from rat brain 
(postnatal day three) and cultured and differentiated for 4 days in a defined media. 
Purified YKL-40 was added every alternate day directly to the OPC differentiation media 
at the indicated concentrations. At the end of differentiation cells were lysed in lysis 
buffer followed western blotting for myelin basic protein, CNPase, and actin proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
 
 
 
 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
 127 
CHAPTER 5 
GEERAL DISCUSSIO AD FUTURE DIRECTIOS 
  
Astrocytes are the most abundant cells in the CNS, and regulate normal as well as 
disease associated functions of neurons. A lot of attention has been focused on the 
understanding of their differentiation, development and function. Indeed, a number of 
signaling pathways, including JAK-STAT, BMP-SMAD and Notch, control their 
differentiation from precursor cells. Recently, NFI family of transcription factors has also 
been shown to control gliogenesis [105]. 
 NFI family consists of four members including, NFI-A, -B, -C and –X. All NFIs 
share a conserved DNA binding domain, and has a variable transactivation domain. Like 
many other transcription factors these can either activate or repress genes in a promoter 
and tissue specific manner. Furthermore, these are expressed in various tissues in an 
overlapping and complex pattern, suggesting their importance during tissue development 
[22]. The expression of NFI-A, -B, and -X was observed in developing neocortex of 
mouse brain, implying their importance in the brain development [27].  
 The functions of NFI-A are well documented in the control of gliogenesis. In 
chick embryo spinal cord, NFI-A and NFI-B has been shown to control the astrocyte 
differentiation [18]. Accordingly, NFI-A knock out animals display phenotype with the 
loss of midline glial population, and a lack of GFAP expression. In addition, NFI-A and 
NFI-B deficient animals show a defect in the crebellar granule neuron migration [160]. 
Before the onset of gliogenesis astrocyte specific genes are methylated and not expressed. 
In fact, demethylation of the astrocyte specific promoters is one of the critical and early 
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events for gliogenesis to occur. Recently an elegant study demonstrated that NFI-A factor 
is critical for the demethylation of promoters during the gliogenesis. However, the exact 
mechanism of this regulation and role of other NFI factors during astrocyte 
differentiation is not clear [25]. 
  NFI-X is also expressed within the developing and adult mouse brain. 
Accordingly, animals lacking Nfix gene showed impaired brain development with loss of 
partial corpus callosum, hydrocephalus and defect in progenitor cell 
migration/differentiation. Furthermore, these animals died postnataly and can survive 
only when fed on a soft chow diet [119]. These studies clearly indicated the importance 
of NFI-X in the brain development. Indeed, we have previously shown that NFI-X is 
expressed during the differentiating astrocytes from human neural progenitors and control 
late astrocyte marker gene expression, including GFAP and SPARCL-1[23].  
 Alternative splicing is a common mechanism to generate many proteins with 
varied function from a same transcript. NFIs also undergo alternative splicing, generating 
as many as 9 splice variants for each gene [26]. There are several splice variants, either 
computer predicted or cloned, of Nfix transcripts. Most likely, these splice isoforms carry 
different functions depending on their protein sequence and structure. Nonetheless, the 
documented NFI-X splice isoforms has been cloned either from mouse or from Xenopus 
[116, 136]. However, the expression and function of NFI-X splice isoforms from human 
CNS cells remained unexplored. 
 In this dissertation, we have analyzed the expression and function of NFI-X splice 
isoforms in primary human astrocytes. A novel human isoform NFI-X3 is cloned and 
characterized. NFI-X3 is unique due to the insertion of exon 9 causing a frame shift in 
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protein sequence and subsequent generation of proline rich C-terminal transactivation 
domain (chapter 2). Surprisingly, this unique proline rich transactivation domain is 
almost 100% conserved among higher mammals and contains more prolines compared to 
the Xenopus NFI-X3 lacking a strong trans-activation potential. Further suggesting that 
NFI-X3 isoform might have acquired additional and unique functions during the 
evolution of higher animals. Indeed, NFI-X3 strongly activates the expression of several 
genes including, GFAP and, SPARCL-1 compared to NFI-X1 (lacking proline rich 
transactivation domain) (chapter 2). Moreover, its expression increases during the invitro 
astrocyte differentiation and precedes the expression of GFAP and SPARCL-1 
suggesting, NFI-X3 is an important regulator of marker gene expression during astrocyte 
differentiation.  
 NFI factors regulate gene expression via different mechanisms including, direct 
binding to its consensus DNA binding element, interaction with various transcription 
factors, and competition with the Sp1 for the binding on adjacent DNA binding elements. 
In another study, NFI-C has been shown to interact with RNA-PolII and may recruit 
transcription initiation machinery to the gene promoters. In addition, these factors may 
interact with histone H3 as part of their mechanism of gene activation [26]. Recently, 
NFI-A has been shown to play a critical role in the demethylation of the astrocyte 
specific genes subsequent activation [25]. Astrocyte specific gene expression also 
depends on the histone-acetylation on specific lysine residues (H3K4) during gliogenesis. 
However, NFI-X3 has no significant effect on methylation of CpG sites within GFAP 
promoter (chapter 2). Chromatin immunoprecipitation revealed no significant changes in 
the H3K4 acetylation levels of GFAP promoter. Moreover, NFI-X3 expressing cells 
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showed two fold enhanced recruitment of RNA-PolII on the GFAP promoter. However, 
the precise mechanism of RNA-PolII recruitment by NFI-X3 remained a quest for future 
work. Direct interaction between RNA-PolII and NFI-X1 or NFI-X3 was similar (data 
not shown), excluding the possibility of RNA-PolII recruitment via NFI-X3-RNA-PolII 
interaction. Since, NFI-C can interact with and bring BRG-1 (a subunit of the chromatin 
remodeling complex) to remodel the promoters [161], we explored the possibility of 
interaction between NFI-X3 and BRG-1. However, we could not detect interaction 
between these proteins in Co-IP experiments, suggesting BRG-1 independent regulation. 
However, an attempt to map the nucleosome position at the TSS of GFAP gene revealed 
no apparent changes in their location. However, possibility of nucleosome remodeling by 
NFI-X3 on GFAP transcription start site can not be excluded. 
 NFIs are critical for normal mouse brain development, and NFI-X is a critical 
regulator of astrocyte marker genes during their differentiation [26, 118]. However, the 
downstream genes regulated by NFIs remained elusive. Microarray analysis performed 
on our NFI-X3 isoform expressing glioma cells identified changes in the expression of 
several genes (data not shown). Interestingly, most of the highly upregulated genes 
encode proteins associated with extracellular matrix (ECM) including, SPARCL-1, YKL-
40, Periostin, TIMP-3, MMP-3, and Thrombospondin 3 (TSP3).  
 ECM plays a critical role in maintaining the tissue homeostasis, and particularly 
during the embryo development, when cells generated from the precursors, in a relatively 
small compartmentalized area, has to migrate out to the distant but proper locations. 
Similarly, SPARCL-1 has been shown to be expressed by radial glia in the embryonic 
CNS and regulate radial glial guided neuronal migration[162]. In addition, SPARCL-1 is 
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expressed in the astrocytic processes ensheathing synaptic connections suggesting its role 
in synapse remodeling [163]. Indeed, unpublished work from Dr. Cagla Eroglu group has 
demonstrated a synaptogenic function for SPARCL-1[163]. Considering the abnormal 
brain development in the NFI-X knock out animals, it is tempting to analyze the 
SPARCL-1 expression and the synaptic structures in these animals. Similarly, a plethora 
of functions are associated with THBS, including angiogenesis, cell migration, and 
proliferation. Interestingly, all the THBS are expressed by astrocytes during early CNS 
development and control synapse formation [4]. Furthermore, THBS-3 is upregulated in 
reactive astrocytes after injury and may help repair synapse formation [78]. TIMP-3 is 
another ECM protein, and controls congintive functions in mice [164]. In addition, 
TIMP-3 is also upregulated in AD and may contribute to the processing of amyloid beta 
peptide [165]. Taken together, ECM proteins play critical role in normal and pathological 
CNS functions. Since, expression and function of YKL-40 in normal brain remained 
unexplored, we sought to address its expression, regulation and function in the CNS cells. 
 YKL-40 also known as CHI3L1 is a secreted ECM protein and is highly 
upregulated in malignant glioblastoma (GBM) [97]. Moreover, its high expression is 
correlated with the invasive GBM tumors and poor prognosis of the patients [166]. 
Accordingly, transformed human astrocytes overexpressing YKL-40 are highly invasive 
and resistant to radiation, suggesting YKL-40 to be a pro-oncogenic factor [153]. In non 
CNS tissue, it is highly expressed during differentiating macrophages from monocytes 
[92]. It is also expressed during the early development of human musculoskeletal system 
[167].  However, its expression and function in developing CNS cells remained elusive. 
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 Here, we provide the evidence for the first time that, YKL-40 is expressed in the 
early postnatal mouse brain developmental period P1 to P21 (Chapter 3). We further 
demonstrate that its expression is increased during astrocyte differentiation in vitro, 
suggesting YKL-40 is produced by astrocytes in the developing brain. Astrocytes can be 
categorized into two major classes based on their location and function within the CNS 
in-vivo. It will be important to establish its expression in the sections of brain in vivo 
using immunohistochemistry, as to what type of regional astrocytes produce YKL-40. It 
is also important to analyze its expression and function in the adult brain.  
 Furthermore, we validated the microarray data of increased YKL-40 expression in 
U373-X3 cells by Q-PCR (chapter 3). Moreover, knockdown of NFI-X3 and NFI-X 
reduced the YKL-40 expression in primary astrocytes. In addition, we also show that 
STAT-3, another factor involved in astrocyte differentiation, controls basal expression of 
YKL-40 in astrocytes. These data indicate that YKL-40 may be an astrocyte specific 
factor in CNS whose expression is controlled by gliogenic transcription factors NFI-X 
and STAT-3. Nevertheless, individual knock down of NFI-A, -B, -C, and –X 
demonstrated that YKL-40 is specifically controlled by NFI-X and to a lesser extent by 
NFI-C (data not shown). It remains interesting to analyze YKL-40 expression in 
individual NFI knock-out animals. 
 We also stimulated primary astrocytes with cytokines of IL-6 family (IL-6 and 
OSM), which both activates JAK-STAT pathway, and show that YKL-40 expression is 
induced. Furthermore, this induced expression is controlled by STAT3 (but not STAT1) 
and to our surprise by NFI-X. Detailed analysis of reporter activity suggested 
indispensable role of STAT and AP-1 elements in the basal and OSM induced YKL-40 
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promoter activation. Interestingly, mutations in the putative NFI binding elements of 
YKL-40 promoter had no significant effect on basal or OSM induced reporter activity. 
This led us to hypothesize that NFI-X could be recruited by STAT3 on a NFI non-
consensus site adjacent to STAT site in the YKL-40 promoter.  
Indeed, we were able to detect STAT3 and STAT1 (data not shown) in NFI-X 
Co-IP experiments. Furthermore, the interaction of STAT3/STAT1 with NFI-X3 was 
significantly more and this interaction was further enhanced after OSM stimulation 
(chapter 3). Whether, this interaction is physiologically relevant and occurs on YKL-40 
promoter will be analyzed in detail in future. Similarly, previous studies has 
demonstrated interaction between STAT3 and NF-κB which controls a different subset of 
genes than by STAT3 [159]. In the same study it was also proposed that STAT3 may 
regulate different subsets of genes by interacting with other transcription factor (s). Since, 
NFI and STAT3 both are critical for astrocyte differentiation; it is possible that other 
astrocyte specific genes may also be regulated by this interaction. It remains open for 
future studies to analyze if the interaction between NFI-X and STAT3 is specific or other 
NFIs (-A, -B, and -C) can also interact with other STAT family members or vice-versa. 
The domains involved in this interaction will also be analyzed.  
 YKL-40 has been shown to control the migration and adhesion of endothelial 
cells [91]. Here, we demonstrate that YKL-40 controls migration of primary astrocytes in 
vitro. Furthermore, NFI-X also controls astrocyte migration likely via regulating YKL-40 
expression (chapter 3). Indeed, NFI-X3 overexpressing glioma cells migrate and invade 
with greater efficiency, and this effect was abolished when YKL-40 expression was 
knockdown. Thus NFI-X controls glioma cell migration and invasion in vitro by 
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regulating YKL-40 expression. Taken together, we would like to propose that YKL-40 
controls astrocyte migration during CNS development, and this normal function of YKL-
40 is utilized by glioma cells (harboring constitutively active STAT3) with elevated 
levels of YKL-40 for their invasive phenotype.  
 Elevated levels of YKL-40 can be identified in micro-array/ proteome analysis of 
most of the CNS pathologies including AD, PD, MS and GBM. We have demonstrated 
that pro-inflammatory cytokines IL-1, IL-6 and OSM can induce YKL-40 expression in 
primary human astrocytes, and this induction was further synergistically activated by 
these cytokines when added in combination (chapter 4). Conversely, microglia are 
irresponsive to cytokine stimulation for YKL-40 expression (chapter 4). Surprisingly, 
YKL-40 was detected in whole cell lysates (WCL) but not in the conditioned media (CM) 
of microglia (in contrast to astrocytes, where YKL-40 is detected in CM but not in WCL) 
suggesting cell type specific regulation of YKL-40 expression and secretion. This data 
clearly suggests that astrocytes are one of the sources for increased YKL-40 levels in 
CNS pathologies. However, the regulation and role of YKL-40 in reactive astrocytes 
remains to be worked on in future. Nevertheless, our data that YKL-40 controls astrocyte 
migration strongly suggests that elevated levels of YKL-40 in reactive astrocytes may 
help them migrate in response to an injury. We have also demonstrated that purified 
YKL-40 inhibits MBP expression during oligodendrocytes differentiation from OPCs 
(chapter 4). Indeed, recently a very elegant study has identified high levels of CSF- YKL-
40 in association with conversion to MS [104].  Since YKL-40 is an anti-apoptotic, pro-
survival and pro-migratory/ chemo-attractant factor, it is speculative that high YKL-40 
levels at the sites of MS lesions (produced by reactive astrocytes) might attract OPCs but 
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simultaneously inhibit their maturation in order to re-myelinate the injured axons.  
However, the precise role of YKL-40 on oligodendrocytes/OPC differentiation remains 
to be elucidated in future studies. In conclusion, YKL-40 could be a very interesting drug 
target for the treatment of MS.  
Based on these data we would like to propose regulation and role of YKL-40 
during CNS inflammation as shown below.  
   
 
 
In conclusion, this dissertation has identified NFI-X3, a novel splice isoform of 
NFI-X, as the major regulator of astrocyte marker genes by a novel mechanism likely via 
 
Endogenous ligand 
(CNS resident macrophage) 
Macrophage) 
YKL-40 ??? 
YKL-40 ??? 
Neuron/ Oligodendrocyte de-myelination 
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nucleosome remodeling/eviction. In addition, NFI-X also controls astrocyte migration 
and glioma cell invasion by regulating the expression of YKL-40, a novel astrocyte 
differentiation associated secreted molecule. YKL-40 expression is also regulated by 
STAT3 another gliogenic factor. We also expand the knowledge of mechanisms of OSM 
induced YKL-40 expression in glioma (tumors). Based on the findings in this 
dissertation, we can draw a model of YKL-40 expression and its hypothetical functions in 
normal and pathology associated CNS. 
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IL-6, OSM 
 137 
 
 
 
 
 
 
 
 
 
Literature Cited 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 138 
1. BA Barres: The mystery and magic of glia: a perspective on their roles in 
health and disease. euron 2008, 60:430-40. 
2. B Stevens: euron-astrocyte signaling in the development and plasticity of 
neural circuits. eurosignals 2008, 16:278-88. 
3. BA Barres, SJ Smith: eurobiology. Cholesterol--making or breaking the 
synapse. Science 2001, 294:1296-7. 
4. KS Christopherson, EM Ullian, CC Stokes, CE Mullowney, JW Hell, A 
Agah, J Lawler, DF Mosher, P Bornstein, BA Barres: Thrombospondins are 
astrocyte-secreted proteins that promote CS synaptogenesis. Cell 2005, 
120:421-33. 
5. B Stevens, J Allen, LE Vazquez, GR Howell, KS Christopherson,  ouri, 
KD Micheva, AK Mehalow, AD Huberman, B Stafford, et al: The classical 
complement cascade mediates CS synapse elimination. Cell 2007, 131:1164-
78. 
6. A Kriegstein, S octor, V Martinez-Cerdeno: Patterns of neural stem and 
progenitor cell division may underlie evolutionary cortical expansion. at 
Rev eurosci 2006, 7:883-90. 
7. FT Merkle, A Alvarez-Buylla: eural stem cells in mammalian development. 
Curr Opin Cell Biol 2006, 18:704-9. 
8. Y Yokota, HT Gashghaei, C Han, H Watson, KJ Campbell, ES Anton: 
Radial glial dependent and independent dynamics of interneuronal 
migration in the developing cerebral cortex. PLoS One 2007, 2:e794. 
9. F Doetsch, I Caille, DA Lim, JM Garcia-Verdugo, A Alvarez-Buylla: 
Subventricular zone astrocytes are neural stem cells in the adult mammalian 
brain. Cell 1999, 97:703-16. 
10. J Silver, JH Miller: Regeneration beyond the glial scar. at Rev eurosci 
2004, 5:146-56. 
11. CK Glass, K Saijo, B Winner, MC Marchetto, FH Gage: Mechanisms 
underlying inflammation in neurodegeneration. Cell, 140:918-34. 
12. H Ilieva, M Polymenidou, DW Cleveland: on-cell autonomous toxicity in 
neurodegenerative disorders: ALS and beyond. J Cell Biol 2009, 187:761-72. 
13.  Ballas, DT Lioy, C Grunseich, G Mandel: on-cell autonomous influence 
of MeCP2-deficient glia on neuronal dendritic morphology. at eurosci 
2009, 12:311-7. 
14. I Maezawa, S Swanberg, D Harvey, JM LaSalle, LW Jin: Rett syndrome 
astrocytes are abnormal and spread MeCP2 deficiency through gap 
junctions. J eurosci 2009, 29:5051-61. 
15. K Saijo, B Winner, CT Carson, JG Collier, L Boyer, MG Rosenfeld, FH 
Gage, CK Glass: A urr1/CoREST pathway in microglia and astrocytes 
protects dopaminergic neurons from inflammation-induced death. Cell 2009, 
137:47-59. 
16. C Dufour, J Cadusseau, P Varlet, AL Surena, GP de Faria, A Dias-Morais,  
Auger,  Leonard, E Daudigeos, C Dantas-Barbosa, et al: Astrocytes 
reverted to a neural progenitor-like state with transforming growth factor 
alpha are sensitized to cancerous transformation. Stem Cells 2009, 27:2373-
82. 
 139 
17. F Barnabe-Heider, JA Wasylnka, KJ Fernandes, C Porsche, M Sendtner, DR 
Kaplan, FD Miller: Evidence that embryonic neurons regulate the onset of 
cortical gliogenesis via cardiotrophin-1. euron 2005, 48:253-65. 
18. B Deneen, R Ho, A Lukaszewicz, CJ Hochstim, RM Gronostajski, DJ 
Anderson: The transcription factor FIA controls the onset of gliogenesis in 
the developing spinal cord. euron 2006, 52:953-68. 
19. T Sanosaka, M amihira, H Asano, J Kohyama, K Aisaki, K Igarashi, J 
Kanno, K akashima: Identification of genes that restrict astrocyte 
differentiation of midgestational neural precursor cells. euroscience 2008, 
155:780-8. 
20. O Hermanson, K Jepsen, MG Rosenfeld: -CoR controls differentiation of 
neural stem cells into astrocytes. ature 2002, 419:934-9. 
21. T Shu, KG Butz, C Plachez, RM Gronostajski, LJ Richards: Abnormal 
development of forebrain midline glia and commissural projections in fia 
knock-out mice. J eurosci 2003, 23:203-12. 
22. S Mason, M Piper, RM Gronostajski, LJ Richards: uclear factor one 
transcription factors in CS development. Mol eurobiol 2009, 39:10-23. 
23. KM Wilczynska, SK Singh, B Adams, L Bryan, RR Rao, K Valerie, S 
Wright, I Griswold-Prenner, T Kordula: uclear factor I isoforms regulate 
gene expression during the differentiation of human neural progenitors to 
astrocytes. Stem Cells 2009, 27:1173-81. 
24. JD Lathia, MP Mattson, A Cheng: otch: from neural development to 
neurological disorders. J eurochem 2008, 107:1471-81. 
25. M amihira, J Kohyama, K Semi, T Sanosaka, B Deneen, T Taga, K 
akashima: Committed neuronal precursors confer astrocytic potential on 
residual neural precursor cells. Dev Cell 2009, 16:245-55. 
26. RM Gronostajski: Roles of the FI/CTF gene family in transcription and 
development. Gene 2000, 249:31-45. 
27. AZ Chaudhry, GE Lyons, RM Gronostajski: Expression patterns of the four 
nuclear factor I genes during mouse embryogenesis indicate a potential role 
in development. Dev Dyn 1997, 208:313-25. 
28. F Besnard, M Brenner, Y akatani, R Chao, HJ Purohit, E Freese: Multiple 
interacting sites regulate astrocyte-specific transcription of the human gene 
for glial fibrillary acidic protein. J Biol Chem 1991, 266:18877-83. 
29. RJ Allore, WC Friend, D O'Hanlon, KM eilson, R Baumal, RJ Dunn, A 
Marks: Cloning and expression of the human S100 beta gene. J Biol Chem 
1990, 265:15537-43. 
30. R Godbout, DA Bisgrove, D Shkolny, RS Day, 3rd: Correlation of B-FABP 
and GFAP expression in malignant glioma. Oncogene 1998, 16:1955-62. 
31. T Inoue, T Tamura, T Furuichi, K Mikoshiba: Isolation of complementary 
DAs encoding a cerebellum-enriched nuclear factor I family that activates 
transcription from the mouse myelin basic protein promoter. J Biol Chem 
1990, 265:19065-70. 
32. G Steele-Perkins, C Plachez, KG Butz, G Yang, CJ Bachurski, SL Kinsman, 
ED Litwack, LJ Richards, RM Gronostajski: The transcription factor gene 
 140 
fib is essential for both lung maturation and brain development. Mol Cell 
Biol 2005, 25:685-98. 
33. K Driller, A Pagenstecher, M Uhl, H Omran, A Berlis, A Grunder, AE 
Sippel: uclear Factor One X deficiency causes brain malformation and 
severe skeletal defects. Mol Cell Biol 2007. 
34. G Steele-Perkins, KG Butz, GE Lyons, M Zeichner-David, HJ Kim, MI Cho, 
RM Gronostajski: Essential role for FI-C/CTF transcription-replication 
factor in tooth root development. Mol Cell Biol 2003, 23:1075-84. 
35. DA Bisgrove, EA Monckton, M Packer, R Godbout: Regulation of brain 
fatty acid-binding protein expression by differential phosphorylation of 
nuclear factor I in malignant glioma cell lines. J Biol Chem 2000, 275:30668-
76. 
36. M Meisterernst, L Rogge, R Foeckler, M Karaghiosoff, EL Winnacker: 
Structural and functional organization of a porcine gene coding for nuclear 
factor I. Biochemistry 1989, 28:8191-200. 
37. TK Kim, RG Roeder: Proline-rich activator CTF1 targets the TFIIB 
assembly step during transcriptional activation. Proc atl Acad Sci U S A 
1994, 91:4170-4. 
38. A Xiao, H Wu, PP Pandolfi, D Louis, T Van Dyke: Astrocyte inactivation of 
the pRb pathway predisposes mice to malignant astrocytoma development 
that is accelerated by PTE mutation. Cancer Cell 2002, 1:157-68. 
39. J Ristiniemi, J Oikarinen: Histone H1 binds to the putative nuclear factor I 
recognition sequence in the mouse alpha 2(I) collagen promoter. J Biol Chem 
1989, 264:2164-74. 
40. MC ehls, RA Rippe, L Veloz, DA Brenner: Transcription factors nuclear 
factor I and Sp1 interact with the murine collagen alpha 1 (I) promoter. Mol 
Cell Biol 1991, 11:4065-73. 
41. AZ Chaudhry, AD Vitullo, RM Gronostajski: uclear factor I-mediated 
repression of the mouse mammary tumor virus promoter is abrogated by the 
coactivators p300/CBP and SRC-1. J Biol Chem 1999, 274:7072-81. 
42. DM Lemke: Epidemiology, diagnosis, and treatment of patients with 
metastatic cancer and high-grade gliomas of the central nervous system. J 
Infus urs 2004, 27:263-9. 
43. J Rich, DD Bigner: Development of novel targeted therapies in the 
treatment of malignant glioma. at Rev Drug Discov 2004, 3:430-46. 
44. SK Singh, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM 
Henkelman, MD Cusimano, PB Dirks: Identification of human brain tumour 
initiating cells. ature 2004, 432:396-401. 
45. SK Singh, ID Clarke, M Terasaki, VE Bonn, C Hawkins, J Squire, PB Dirks: 
Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 
63:5821-8. 
46. S Bao, Q Wu, RE McLendon, Y Hao, Q Shi, AB Hjelmeland, MW Dewhirst, 
DD Bigner, J Rich: Glioma stem cells promote radioresistance by 
preferential activation of the DA damage response. ature 2006, 444:756-
60. 
 141 
47. G Liu, X Yuan, Z Zeng, P Tunici, H g, IR Abdulkadir, L Lu, D Irvin, KL 
Black, JS Yu: Analysis of gene expression and chemoresistance of CD133+ 
cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67. 
48. VS Donnenberg, AD Donnenberg: Multiple drug resistance in cancer 
revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005, 45:872-7. 
49. SH Chen, E Benveniste: Oncostatin M: a pleiotropic cytokine in the central 
nervous system. Cytokine Growth Factor Rev 2004, 15:379-91. 
50. ML Vignais, HB Sadowski, D Watling, C Rogers, M Gilman: Platelet-
derived growth factor induces phosphorylation of multiple JAK family 
kinases and STAT proteins. Mol Cell Biol 1996, 16:1759-69. 
51. DW Leaman, S Pisharody, TW Flickinger, MA Commane, J Schlessinger, 
IM Kerr, DE Levy, GR Stark: Roles of JAKs in activation of STATs and 
stimulation of c-fos gene expression by epidermal growth factor. Mol Cell 
Biol 1996, 16:369-75. 
52. MA Olayioye, I Beuvink, K Horsch, JM Daly, E Hynes: ErbB receptor-
induced activation of stat transcription factors is mediated by Src tyrosine 
kinases. J Biol Chem 1999, 274:17209-18. 
53. DE Levy, JE Darnell, Jr.: Stats: transcriptional control and biological 
impact. at Rev Mol Cell Biol 2002, 3:651-62. 
54. H Yu, D Pardoll, R Jove: STATs in cancer inflammation and immunity: a 
leading role for STAT3. at Rev Cancer 2009, 9:798-809. 
55. MJ Ibarra-Sanchez, PD Simoncic, FR estel, P Duplay, WS Lapp, ML 
Tremblay: The T-cell protein tyrosine phosphatase. Semin Immunol 2000, 
12:379-86. 
56.  Aoki, T Matsuda: A nuclear protein tyrosine phosphatase TC-PTP is a 
potential negative regulator of the PRL-mediated signaling pathway: 
dephosphorylation and deactivation of signal transducer and activator of 
transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 2002, 16:58-
69. 
57.  Aoki, T Matsuda: A cytosolic protein-tyrosine phosphatase PTP1B 
specifically dephosphorylates and deactivates prolactin-activated STAT5a 
and STAT5b. J Biol Chem 2000, 275:39718-26. 
58. DL Krebs, DJ Hilton: SOCS proteins: negative regulators of cytokine 
signaling. Stem Cells 2001, 19:378-87. 
59. E Pinteaux, P Trotter, A Simi: Cell-specific and concentration-dependent 
actions of interleukin-1 in acute brain inflammation. Cytokine 2009, 45:1-7. 
60. RE Mrak, WS Griffin: Interleukin-1, neuroinflammation, and Alzheimer's 
disease. eurobiol Aging 2001, 22:903-8. 
61. J Rothwell, G Luheshi: Interleukin 1 in the brain: biology, pathology and 
therapeutic target. Trends eurosci 2000, 23:618-25. 
62. SM Lucas, J Rothwell, RM Gibson: The role of inflammation in CS 
injury and disease. Br J Pharmacol 2006, 147 Suppl 1:S232-40. 
63. CH Hannum, CJ Wilcox, WP Arend, FG Joslin, DJ Dripps, PL Heimdal, LG 
Armes, A Sommer, SP Eisenberg, RC Thompson: Interleukin-1 receptor 
antagonist activity of a human interleukin-1 inhibitor. ature 1990, 343:336-
40. 
 142 
64. CA Davies, SA Loddick, S Toulmond, RP Stroemer, J Hunt, J Rothwell: 
The progression and topographic distribution of interleukin-1beta expression 
after permanent middle cerebral artery occlusion in the rat. J Cereb Blood 
Flow Metab 1999, 19:87-98. 
65. VL Pearson, J Rothwell, S Toulmond: Excitotoxic brain damage in the rat 
induces interleukin-1beta protein in microglia and astrocytes: correlation 
with the progression of cell death. Glia 1999, 25:311-23. 
66. F Blasi, M Riccio, A Brogi, M Strazza, ML Taddei, S Romagnoli, A Luddi, R 
D'Angelo, S Santi, E Costantino-Ceccarini, et al: Constitutive expression of 
interleukin-1beta (IL-1beta) in rat oligodendrocytes. Biol Chem 1999, 
380:259-64. 
67. LA O'eill, C Greene: Signal transduction pathways activated by the IL-1 
receptor family: ancient signaling machinery in mammals, insects, and 
plants. J Leukoc Biol 1998, 63:650-7. 
68. AT Argaw, Y Zhang, BJ Snyder, ML Zhao,  Kopp, SC Lee, CS Raine, CF 
Brosnan, GR John: IL-1beta regulates blood-brain barrier permeability via 
reactivation of the hypoxia-angiogenesis program. J Immunol 2006, 
177:5574-84. 
69. JM Vela, E Molina-Holgado, A Arevalo-Martin, G Almazan, C Guaza: 
Interleukin-1 regulates proliferation and differentiation of oligodendrocyte 
progenitor cells. Mol Cell eurosci 2002, 20:489-502. 
70. C Davis, I Tabarean, S Gaidarova, MM Behrens, T Bartfai: IL-1beta 
induces a MyD88-dependent and ceramide-mediated activation of Src in 
anterior hypothalamic neurons. J eurochem 2006, 98:1379-89. 
71. C Davis, E Mann, MM Behrens, S Gaidarova, M Rebek, J Rebek, Jr., T 
Bartfai: MyD88-dependent and -independent signaling by IL-1 in neurons 
probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc 
atl Acad Sci U S A 2006, 103:2953-8. 
72. PJ Strijbos, J Rothwell: Interleukin-1 beta attenuates excitatory amino 
acid-induced neurodegeneration in vitro: involvement of nerve growth 
factor. J eurosci 1995, 15:3468-74. 
73. M Pizzi, F Goffi, F Boroni, M Benarese, SE Perkins, HC Liou, P Spano: 
Opposing roles for F-kappa B/Rel factors p65 and c-Rel in the modulation 
of neuron survival elicited by glutamate and interleukin-1beta. J Biol Chem 
2002, 277:20717-23. 
74. L Santambrogio, SL Belyanskaya, FR Fischer, B Cipriani, CF Brosnan, P 
Ricciardi-Castagnoli, LJ Stern, JL Strominger, R Riese: Developmental 
plasticity of CS microglia. Proc atl Acad Sci U S A 2001, 98:6295-300. 
75. R Hohlfeld, M Kerschensteiner, E Meinl: Dual role of inflammation in CS 
disease. eurology 2007, 68:S58-63; discussion S91-6. 
76. O euhaus, C Farina, A Yassouridis, H Wiendl, F Then Bergh, T Dose, H 
Wekerle, R Hohlfeld: Multiple sclerosis: comparison of copolymer-1- 
reactive T cell lines from treated and untreated subjects reveals cytokine 
shift from T helper 1 to T helper 2 cells. Proc atl Acad Sci U S A 2000, 
97:7452-7. 
 143 
77. MD Laird, JR Vender, KM Dhandapani: Opposing roles for reactive 
astrocytes following traumatic brain injury. eurosignals 2008, 16:154-64. 
78. J Liauw, S Hoang, M Choi, C Eroglu, M Choi, GH Sun, M Percy, B 
Wildman-Tobriner, T Bliss, RG Guzman, et al: Thrombospondins 1 and 2 
are necessary for synaptic plasticity and functional recovery after stroke. J 
Cereb Blood Flow Metab 2008, 28:1722-32. 
79. A Mantovani, P Allavena, A Sica, F Balkwill: Cancer-related inflammation. 
ature 2008, 454:436-44. 
80. E Voronov, DS Shouval, Y Krelin, E Cagnano, D Benharroch, Y Iwakura, 
CA Dinarello, R Apte: IL-1 is required for tumor invasiveness and 
angiogenesis. Proc atl Acad Sci U S A 2003, 100:2645-50. 
81. S Grivennikov, M Karin: Autocrine IL-6 signaling: a key event in 
tumorigenesis? Cancer Cell 2008, 13:7-9. 
82. PW Szlosarek, FR Balkwill: Tumour necrosis factor alpha: a potential target 
for the therapy of solid tumours. Lancet Oncol 2003, 4:565-73. 
83. JR Grandis, SD Drenning, A Chakraborty, MY Zhou, Q Zeng, AS Pitt, DJ 
Tweardy: Requirement of Stat3 but not Stat1 activation for epidermal 
growth factor receptor- mediated cell growth In vitro. J Clin Invest 1998, 
102:1385-92. 
84. T Bowman, MA Broome, D Sinibaldi, W Wharton, WJ Pledger, JM Sedivy, 
R Irby, T Yeatman, SA Courtneidge, R Jove: Stat3-mediated Myc expression 
is required for Src transformation and PDGF-induced mitogenesis. Proc atl 
Acad Sci U S A 2001, 98:7319-24. 
85. M Kortylewski, M Kujawski, T Wang, S Wei, S Zhang, S Pilon-Thomas, G 
iu, H Kay, J Mule, WG Kerr, et al: Inhibiting Stat3 signaling in the 
hematopoietic system elicits multicomponent antitumor immunity. at Med 
2005, 11:1314-21. 
86. H Yu, M Kortylewski, D Pardoll: Crosstalk between cancer and immune 
cells: role of STAT3 in the tumour microenvironment. at Rev Immunol 
2007, 7:41-51. 
87. J Bollrath, TJ Phesse, VA von Burstin, T Putoczki, M Bennecke, T Bateman, 
T ebelsiek, T Lundgren-May, O Canli, S Schwitalla, et al: gp130-mediated 
Stat3 activation in enterocytes regulates cell survival and cell-cycle 
progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-
102. 
88. H Lee, A Herrmann, JH Deng, M Kujawski, G iu, Z Li, S Forman, R Jove, 
DM Pardoll, H Yu: Persistently activated Stat3 maintains constitutive F-
kappaB activity in tumors. Cancer Cell 2009, 15:283-93. 
89. EC Brantley, E Benveniste: Signal transducer and activator of 
transcription-3: a molecular hub for signaling pathways in gliomas. Mol 
Cancer Res 2008, 6:675-84. 
90. H Ling, AD Recklies: The chitinase 3-like protein human cartilage 
glycoprotein 39 inhibits cellular responses to the inflammatory cytokines 
interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004, 380:651-9. 
 144 
91. J Kzhyshkowska, A Gratchev, S Goerdt: Human chitinases and chitinase-
like proteins as indicators for inflammation and cancer. Biomark Insights 
2007, 2:128-46. 
92. M Rehli, HH iller, C Ammon, S Langmann, L Schwarzfischer, R 
Andreesen, SW Krause: Transcriptional regulation of CHI3L1, a marker 
gene for late stages of macrophage differentiation. J Biol Chem 2003, 
278:44058-67. 
93. AD Recklies, H Ling, C White, SM Bernier: Inflammatory cytokines induce 
production of CHI3L1 by articular chondrocytes. J Biol Chem 2005, 
280:41213-21. 
94. CG Lee, D Hartl, GR Lee, B Koller, H Matsuura, CA Da Silva, MH Sohn, L 
Cohn, RJ Homer, AA Kozhich, et al: Role of breast regression protein 39 
(BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and 
apoptosis. J Exp Med 2009, 206:1149-66. 
95. KP Bhat, CE Pelloski, Y Zhang, SH Kim, C deLaCruz, M Rehli, KD Aldape: 
Selective repression of YKL-40 by F-kappaB in glioma cell lines involves 
recruitment of histone deacetylase-1 and -2. FEBS Lett 2008, 582:3193-200. 
96.  Junker, JS Johansen, LT Hansen, EL Lund, PE Kristjansen: Regulation of 
YKL-40 expression during genotoxic or microenvironmental stress in human 
glioblastoma cells. Cancer Sci 2005, 96:183-90. 
97. MK Tanwar, MR Gilbert, EC Holland: Gene expression microarray analysis 
reveals YKL-40 to be a potential serum marker for malignant character in 
human glioma. Cancer Res 2002, 62:4364-8. 
98. R Shao, K Hamel, L Petersen, QJ Cao, RB Arenas, C Bigelow, B Bentley, W 
Yan: YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. 
Oncogene 2009, 28:4456-68. 
99. AD Recklies, C White, H Ling: The chitinase 3-like protein human cartilage 
glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-
tissue cells and activates both extracellular signal-regulated kinase- and 
protein kinase B-mediated signalling pathways. Biochem J 2002, 365:119-26. 
100. SV Subramanian, ML Fitzgerald, M Bernfield: Regulated shedding of 
syndecan-1 and -4 ectodomains by thrombin and growth factor receptor 
activation. J Biol Chem 1997, 272:14713-20. 
101. JA Buczek-Thomas, MA ugent: Elastase-mediated release of heparan 
sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for 
basic fibroblast growth factor (bFGF) release and attenuation of bfgf binding 
following elastase-induced injury. J Biol Chem 1999, 274:25167-72. 
102. D Bonneh-Barkay, SJ Bissel, G Wang, K Fish, GC icholl, SW Darko, R 
Medina-Flores, M Murphey-Corb, PA Rajakumar, J yaundi, et al: YKL-
40, a marker of simian immunodeficiency virus encephalitis, modulates the 
biological activity of basic fibroblast growth factor. Am J Pathol 2008, 
173:130-43. 
103. CA Colton, RT Mott, H Sharpe, Q Xu, WE Van ostrand, MP Vitek: 
Expression profiles for macrophage alternative activation genes in AD and in 
mouse models of AD. J euroinflammation 2006, 3:27. 
 145 
104. M Comabella, M Fernandez, R Martin, S Rivera-Vallve, E Borras, C Chiva, 
E Julia, A Rovira, E Canto, JC Alvarez-Cermeno, et al: Cerebrospinal fluid 
chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. 
Brain, 133:1082-93. 
105. FD Miller, AS Gauthier: Timing is everything: making neurons versus glia in 
the developing cortex. euron 2007, 54:357-69. 
106. S Fukuda, M Abematsu, H Mori, M Yanagisawa, T Kagawa, K akashima, 
A Yoshimura, T Taga: Potentiation of astrogliogenesis by STAT3-mediated 
activation of bone morphogenetic protein-Smad signaling in neural stem 
cells. Mol Cell Biol 2007, 27:4931-7. 
107. WA Gomes, MF Mehler, JA Kessler: Transgenic overexpression of BMP4 
increases astroglial and decreases oligodendroglial lineage commitment. Dev 
Biol 2003, 255:164-77. 
108.  Gaiano, JS ye, G Fishell: Radial glial identity is promoted by otch1 
signaling in the murine forebrain. euron 2000, 26:395-404. 
109. W Ge, K Martinowich, X Wu, F He, A Miyamoto, G Fan, G Weinmaster, YE 
Sun: otch signaling promotes astrogliogenesis via direct CSL-mediated glial 
gene activation. J eurosci Res 2002, 69:848-60. 
110. B Cebolla, M Vallejo: uclear factor-I regulates glial fibrillary acidic protein 
gene expression in astrocytes differentiated from cortical precursor cells. J 
eurochem 2006, 97:1057-70. 
111. K Krohn, I Rozovsky, P Wals, B Teter, CP Anderson, CE Finch: Glial 
fibrillary acidic protein transcription responses to transforming growth 
factor-beta1 and interleukin-1beta are mediated by a nuclear factor-1-like 
site in the near-upstream promoter. J eurochem 1999, 72:1353-61. 
112. K Amemiya, R Traub, L Durham, EO Major: Adjacent nuclear factor-1 and 
activator protein binding sites in the enhancer of the neurotropic JC virus. A 
common characteristic of many brain-specific genes. J Biol Chem 1992, 
267:14204-11. 
113. L das eves, CS Duchala, F Tolentino-Silva, MA Haxhiu, C Colmenares, WB 
Macklin, CE Campbell, KG Butz, RM Gronostajski: Disruption of the 
murine nuclear factor I-A gene (fia) results in perinatal lethality, 
hydrocephalus, and agenesis of the corpus callosum. Proc atl Acad Sci U S 
A 1999, 96:11946-51. 
114. K akashima, M Yanagisawa, H Arakawa,  Kimura, T Hisatsune, M 
Kawabata, K Miyazono, T Taga: Synergistic signaling in fetal brain by 
STAT3-Smad1 complex bridged by p300. Science 1999, 284:479-82. 
115. C Santoro,  Mermod, PC Andrews, R Tjian: A family of human CCAAT-
box-binding proteins active in transcription and DA replication: cloning 
and expression of multiple cDAs. ature 1988, 334:218-24. 
116. E Roulet, MT Armentero, G Krey, B Corthesy, C Dreyer,  Mermod, W 
Wahli: Regulation of the DA-binding and transcriptional activities of 
Xenopus laevis FI-X by a novel C-terminal domain. Mol Cell Biol 1995, 
15:5552-62. 
 146 
117. G Barry, M Piper, C Lindwall, R Moldrich, S Mason, E Little, A Sarkar, S 
Tole, RM Gronostajski, LJ Richards: Specific glial populations regulate 
hippocampal morphogenesis. J eurosci 2008, 28:12328-40. 
118. K Driller, A Pagenstecher, M Uhl, H Omran, A Berlis, A Grunder, AE 
Sippel: uclear factor I X deficiency causes brain malformation and severe 
skeletal defects. Mol Cell Biol 2007, 27:3855-3867. 
119. CE Campbell, M Piper, C Plachez, YT Yeh, JS Baizer, JM Osinski, ED 
Litwack, LJ Richards, RM Gronostajski: The transcription factor fix is 
essential for normal brain development. BMC Dev Biol 2008, 8:52. 
120. V Pekarik, JC Belmonte: FIX - one gene, two knockouts, multiple effects. J 
Biol 2008, 7:29. 
121. KM Wilczynska, SK Singh, B Adams, L Bryan, RR Rao, K Valerie, S 
Wright, I Griswold-Prenner, T Kordula: uclear Factor I isoforms regulate 
gene expression during the differentiation of human neural progenitors to 
astrocytes. Stem Cells 2009:Published online in STEM CELLS Express 
February 12, 2009. 
122. H Vihma, P Pruunsild, T Timmusk: Alternative splicing and expression of 
human and mouse FAT genes. Genomics 2008, 92:279-91. 
123. MF Arteaga, T Coric, C Straub, CM Canessa: A brain-specific SGK1 splice 
isoform regulates expression of ASIC1 in neurons. Proc atl Acad Sci U S A 
2008, 105:4459-64. 
124. HY Chu, A Ohtoshi: Cloning and functional analysis of hypothalamic 
homeobox gene Bsx1a and its isoform, Bsx1b. Mol Cell Biol 2007, 27:3743-9. 
125. SK Michelhaugh, H Vaitkevicius, J Wang, M Bouhamdan, AR Krieg, JL 
Walker, V Mendiratta, MJ Bannon: Dopamine neurons express multiple 
isoforms of the nuclear receptor nurr1 with diminished transcriptional 
activity. J eurochem 2005, 95:1342-50. 
126. U Kruse, AE Sippel: The genes for transcription factor nuclear factor I give 
rise to corresponding splice variants between vertebrate species. J Mol Biol 
1994, 238:860-5. 
127. H Altmann, W Wendler, EL Winnacker: Transcriptional activation by CTF 
proteins is mediated by a bipartite low-proline domain. Proc atl Acad Sci U 
S A 1994, 91:3901-5. 
128. A Grunder, F Qian, TT Ebel, A Mincheva, P Lichter, U Kruse, AE Sippel: 
Genomic organization, splice products and mouse chromosomal localization 
of genes for transcription factor uclear Factor One. Gene 2003, 304:171-81. 
129. T Kordula, RE Rydel, EF Brigham, F Horn, PC Heinrich, J Travis: 
Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor 
complex regulate alpha1-antichymotrypsin expression in human cortical 
astrocytes. J Biol Chem 1998, 273:4112-8. 
130. SM Gopalan, KM Wilczynska, BS Konik, L Bryan, T Kordula: uclear 
factor-1-X regulates astrocyte-specific expression of the alpha1-
antichymotrypsin and glial fibrillary acidic protein genes. J Biol Chem 2006, 
281:13126-33. 
 147 
131. WS el-Deiry, T Tokino, VE Velculescu, DB Levy, R Parsons, JM Trent, D 
Lin, WE Mercer, KW Kinzler, B Vogelstein: WAF1, a potential mediator of 
p53 tumor suppression. Cell 1993, 75:817-25. 
132. R Mudhasani, JD Fontes: The class II transactivator requires brahma-
related gene 1 to activate transcription of major histocompatibility complex 
class II genes. Mol Cell Biol 2002, 22:5019-26. 
133. W Al-Kandari, R Koneni, V avalgund, A Aleksandrova, S Jambunathan, 
JD Fontes: The zinc finger proteins ZXDA and ZXDC form a complex that 
binds CIITA and regulates MHC II gene transcription. J Mol Biol 2007, 
369:1175-87. 
134. AM Delegeane, LH Ferland, PL Mellon: Tissue-specific enhancer of the 
human glycoprotein hormone alpha- subunit gene: dependence on cyclic 
AMP-inducible elements. Mol Cell Biol 1987, 7:3994-4002. 
135. S Ouellet, F Vigneault, M Lessard, S Leclerc, R Drouin, SL Guerin: 
Transcriptional regulation of the cyclin-dependent kinase inhibitor 1A (p21) 
gene by FI in proliferating human cells. ucleic Acids Res 2006, 34:6472-87. 
136. G ebl, AC Cato: FI/X proteins: a class of FI family of transcription 
factors with positive and negative regulatory domains. Cell Mol Biol Res 
1995, 41:85-95. 
137. C Jiang, BF Pugh: ucleosome positioning and gene regulation: advances 
through genomics. at Rev Genet 2009, 10:161-72. 
138. BR Cairns: The logic of chromatin architecture and remodelling at 
promoters. ature 2009, 461:193-8. 
139.  Gevry, A Svotelis, M Larochelle, L Gaudreau: ucleosome mapping. 
Methods Mol Biol 2009, 543:281-91. 
140. T Tamura, M Miura, K Ikenaka, K Mikoshiba: Analysis of transcription 
control elements of the mouse myelin basic protein gene in HeLa cell 
extracts: demonstration of a strong FI-binding motif in the upstream 
region. ucleic Acids Res 1988, 16:11441-59. 
141. ML Schwartz, Y Hua, R Canete-Soler, WW Schlaepfer: Characterization of 
the mouse neurofilament light (F-L) gene promoter by in vitro 
transcription. Brain Res Mol Brain Res 1998, 57:21-30. 
142. C Plachez, C Lindwall,  Sunn, M Piper, RX Moldrich, CE Campbell, JM 
Osinski, RM Gronostajski, LJ Richards: uclear factor I gene expression in 
the developing forebrain. J Comp eurol 2008, 508:385-401. 
143. K agata, RA Guggenheimer, T Enomoto, JH Lichy, J Hurwitz: Adenovirus 
DA replication in vitro: identification of a host factor that stimulates 
synthesis of the preterminal protein-dCMP complex. Proc atl Acad Sci U S 
A 1982, 79:6438-42. 
144. V Ravichandran, BF Sabath, P Jensen, SA Houff, EO Major: Interactions 
between c-Jun, nuclear factor 1, and JC virus promoter sequences: 
implications for viral tropism. J Virol 2006, 80:10506-13. 
145. K Muller,  Mermod: The histone-interacting domain of nuclear factor I 
activates simian virus 40 DA replication in vivo. J Biol Chem 2000, 
275:1645-50. 
 148 
146. LH Zhao, XQ Ba, XG Wang, XJ Zhu, L Wang, XL Zeng: BAF complex is 
closely related to and interacts with F1/CTF and RA polymerase II in 
gene transcriptional activation. Acta Biochim Biophys Sin (Shanghai) 2005, 
37:440-6. 
147. A O'Donnell, SH Yang, AD Sharrocks: MAP kinase-mediated c-fos 
regulation relies on a histone acetylation relay switch. Mol Cell 2008, 29:780-
5. 
148. BE Hakala, C White, AD Recklies: Human cartilage gp-39, a major secretory 
product of articular chondrocytes and synovial cells, is a mammalian 
member of a chitinase protein family. J Biol Chem 1993, 268:25803-10. 
149. K Kawamura, T Shibata, O Saget, D Peel, PJ Bryant: A new family of 
growth factors produced by the fat body and active on Drosophila imaginal 
disc cells. Development 1999, 126:211-9. 
150. M Yanagisawa, K akashima, T Taga: STAT3-mediated astrocyte 
differentiation from mouse fetal neuroepithelial cells by mouse oncostatin M. 
eurosci Lett 1999, 269:169-72. 
151. BS Paugh, L Bryan, SW Paugh, KM Wilczynska, SM Alvarez, SK Singh, D 
Kapitonov, H Rokita, S Wright, I Griswold-Prenner, et al: Interleukin-1 
regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol 
Chem 2009, 284:3408-17. 
152. JD Cahoy, B Emery, A Kaushal, LC Foo, JL Zamanian, KS Christopherson, 
Y Xing, JL Lubischer, PA Krieg, SA Krupenko, et al: A transcriptome 
database for astrocytes, neurons, and oligodendrocytes: a new resource for 
understanding brain development and function. J eurosci 2008, 28:264-78. 
153. JM igro, A Misra, L Zhang, I Smirnov, H Colman, C Griffin,  Ozburn, M 
Chen, E Pan, D Koul, et al: Integrated array-comparative genomic 
hybridization and expression array profiles identify clinically relevant 
molecular subtypes of glioblastoma. Cancer Res 2005, 65:1678-86. 
154.  Underhill-Day, JK Heath: Oncostatin M (OSM) cytostasis of breast tumor 
cells: characterization of an OSM receptor beta-specific kernel. Cancer Res 
2006, 66:10891-901. 
155. A Kasza, DL Kiss, S Gopalan, W Xu, RE Rydel, A Koj, T Kordula: 
Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M 
and interleukin-1 in human astrocytes. J eurochem 2002, 83:696-703. 
156. BE Deverman, PH Patterson: Cytokines and CS development. euron 
2009, 64:61-78. 
157. KM Wilczynska, SM Gopalan, M Bugno, A Kasza, BS Konik, L Bryan, S 
Wright, I Griswold-Prenner, T Kordula: A novel mechanism of tissue 
inhibitor of metalloproteinases-1 activation by interleukin-1 in primary 
human astrocytes. J Biol Chem 2006, 281:34955-64. 
158. HI Chen, M Sudol: The WW domain of Yes-associated protein binds a 
proline-rich ligand that differs from the consensus established for Src 
homology 3-binding modules. Proc atl Acad Sci U S A 1995, 92:7819-23. 
159. J Yang, M Chatterjee-Kishore, SM Staugaitis, H guyen, K Schlessinger, DE 
Levy, GR Stark: ovel roles of unphosphorylated STAT3 in oncogenesis and 
transcriptional regulation. Cancer Res 2005, 65:939-47. 
 149 
160. W Wang, D Mullikin-Kilpatrick, JE Crandall, RM Gronostajski, ED 
Litwack, DL Kilpatrick: uclear factor I coordinates multiple phases of 
cerebellar granule cell development via regulation of cell adhesion molecules. 
J eurosci 2007, 27:6115-27. 
161. R Liu, H Liu, X Chen, M Kirby, PO Brown, K Zhao: Regulation of CSF1 
promoter by the SWI/SF-like BAF complex. Cell 2001, 106:309-18. 
162. V Gongidi, C Ring, M Moody, R Brekken, EH Sage, P Rakic, ES Anton: 
SPARC-like 1 regulates the terminal phase of radial glia-guided migration in 
the cerebral cortex. euron 2004, 41:57-69. 
163. C Eroglu: The role of astrocyte-secreted matricellular proteins in central 
nervous system development and function. J Cell Commun Signal 2009. 
164. Y Baba, O Yasuda, Y Takemura, Y Ishikawa, M Ohishi, J Iwanami, M 
Mogi,  Doe, M Horiuchi,  Maeda, et al: Timp-3 deficiency impairs 
cognitive function in mice. Lab Invest 2009, 89:1340-7. 
165. HS Hoe, MJ Cooper, MP Burns, PA Lewis, M van der Brug, G Chakraborty, 
CM Cartagena, DT Pak, MR Cookson, GW Rebeck: The metalloprotease 
inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E 
receptor proteolysis. J eurosci 2007, 27:10895-905. 
166. CE Pelloski, A Mahajan, M Maor, EL Chang, S Woo, M Gilbert, H Colman, 
H Yang, A Ledoux, H Blair, et al: YKL-40 expression is associated with 
poorer response to radiation and shorter overall survival in glioblastoma. 
Clin Cancer Res 2005, 11:3326-34. 
167. JS Johansen, PE Hoyer, LA Larsen, PA Price, K Mollgard: YKL-40 protein 
expression in the early developing human musculoskeletal system. J 
Histochem Cytochem 2007, 55:1213-28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150 
 
VITA 
 
 
SADEEP KUMAR SIGH 
Department of Biochemistry and Molecular Biology 
Virginia Commonwealth University School of Medicine 
1101 East marshall St., Room 2-016n 
Richmond, VA 23298, USA 
Phone: 804-828-4884 
Email: singhsk@vcu.edu 
 
 
 
PERSOAL IFORMATIO 
 
Date of Birth                         January 10
th
 1981 
Place of Birth                        Mirzapur, India 
Citizenship                            Indian 
Visa Status                            F1 (Student Visa) 
 
EDUCATIO 
 
PhD                                   Biochemistry and Molecular Biology, Virginia Commonwealth 
University, 2010 
M.Sc. Biotechnology, Jawaharlal Nehru University, 2004 
 
 
AWARDS 
 
2010 Young Investigator’s Educational Enhancement (YIEE) award American 
Society for Neurochemistry (ASN) 2010. 
2010 Graduate School Thesis/Dissertation Assistantship award, School of 
Medicine, Virginia Commonwealth University, Richmond, VA 
2009-10           Phi Kappa Phi Honor Society Nominee Award, Virginia Commonwealth 
University Phi Kappa Phi Chapter. 
2004-05 Junior Research Fellowship, Council of Scientific and Industrial Research, 
New Delhi, India  
2004  Selected for Shyama Prasad Mukherjee Fellowship Test, Council of    
Scientific and   Industrial research, New Delhi, India 
2002-2004 Stipend for Outstanding Students of  Master’s in Biotechnology, 
Department of Biotechnology, Ministry of Science and Technology, India 
 
 
PUBLICATIOS 
 151 
 
1. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, 
Marmorstein R, Kordula T, Milstien S, Spiegel S. Regulation of histone 
acetylation in the nucleus by Sphingosine-1-Phosphate. Science. 2009 Sep; Vol. 
325. no. 5945, pp. 1254 - 57. 
 
2. Wilczynska KM, Singh SK, Adams B, Bryan L, Rao RR, Valerie K, Wright S, 
Griswold-Prenner I, Kordula T. Nuclear factor I isoforms regulate gene 
expression during the differentiation of human neural progenitors to astrocytes. 
Stem Cells. 2009 May; 27(5):1173-81. 
 
3. Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, Singh SK, 
Kapitonov D, Rokita H, Wright S, Griswold-Prenner I, Milstien S, Spiegel S, 
Kordula T. IL-1 regulates expression of Sphingosine kinase 1 in glioblastoma 
cells. J Biol Chem. 2009 Feb 6;284(6):3408-17 
 
4. Bryan, L, Paugh BS, , Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, 
Milstien S, Spiegel S, Kordula T. Sphingosine-1-phosphate and interleukin 1 
cooperatively regulate the plasminogen activator system in gliomas; implications 
for invasion. Mol Cancer Res. 6(9):1469-77. 2008. 
 
5. Wilczynska KM, Szelag M, Alvarez SM, Singh SK, Paugh B, Bryan L, Fillmore 
H, Fang X, Kordula T. Constitutively active STAT3 promotes the growth of 
oligodendroglioma tumors. Submitted to J. euroinflammation 2010 (under 
revision) 
 
6. Singh SK, Wilczynska KM, Grzybowski A, Osrah B, Yester J, Bryan L, Wright 
S, Griswold-Prenner I, Kordula T.  The unique transcriptional activation domain 
of the Nuclear Factor-I-X3 stimulates astrocyte gene expression via inducing the 
alteration of local nucleosomal architecture. Resubmitted to J Biol Chem. 2010 
 
7.   Singh SK, Wilczynska KM, Bryan L, Dumur K, Wright S, Griswold-Prenner I, 
Kordula T. Regulation and role of YKL-40 in glial cell function. Manuscript in 
preparation 
 
 
